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CHAPTER I 
HISTORICAL 
Cancer Che~otherapy - General Background 
In 1937, the National Cancer Institute Act201 was signed by 
President Franklin D. Roosevelt to establish "in the public health 
service a division which shall be known as the National Cancer Institute 
." in order to conduct ". studies relating to the cause, diagno-
sis and treatment of cancer." Thirty-eight years have elapsed since the 
act of 1937. Man has embarked on a great voyage of significant discov-
eries. 
Cancer is a generic term used for a large number and wide variety 
of malignant neoplasms, affecting the different organs and systems of 
the body. The etiology of cancer in a very few cases such as exposure 
to carcinogenic hydrocarbons or to excessive radiation or to action of 
viruses is only somewhat understood. In spite of intensive and prodi-
gious efforts by countless medicai investigators throughout the world, 
the "real" cause of cancer in human remains an enigma. Since any of 
the human body tissues may be affected by cancer, types of malignancies 
at present can only be discussed in a very general way, as malignant 
neoplasms of: (1) buccal cavity and pharynx, (2) digestive organs and 
peritoneum, (3) respiratory system, (4) breast and genitourinary organs, 
(5) lymphatic and hematopoietic tissues, and (6) other and unspecified 
sites. 
1 
One of the most crucial deficiencies of present cancer therapy 
appears to be the difficulty of detecting tumors at the beginning of 
the growth, when therapy has a high degree of success. By the time 
symptoms of cancer are discerned, it has usually metastasized and cure 
b l "k 1 177 ecomes very un 1 e y. The main cancer therapeutic modalities of 
current use are surgery, radiation therapy, chemotherapy, immunotherapy 
and/or a combination32 of one of these with another. 
The rapidly growing interest and activity in cancer chemotherapy 
parallels an energetic, world-wide investigation of the elucidation of 
the molecular basis of action of drugs which may affect, among other 
things, nucleic acid or portein synthesis with selectivity and specif-
icity. The underlying anticipation is that such information may well 
2 
be utilized in the design of new drugs or modification of old ones which 
are currently being used as anticancer drugs. 
It is well known that usefulness of many drugs stems from the fact 
that the cells of some tumors grow and divide more rapidly than do cells 
of most normal tissues. Thus the drug kills tumor cells faster than 
normal cells. 
Until the present century, most drugs were fortuitously discovered 
products of nature. Discovery and development of a new drug now usually 
evolves from a combination of systematic, planned experiments and acci-
dental or unexpected observations. Only a handful of all the compounds 
for which activity in experimental animal systems have been claimed, 
have clinical utility. The current chemical status of cancer chemo-
therapy have been categorically summarized as (Tables I, II, III, IV, 
and V) 93 ,l7l,ZSZ (1) alkylating agents, (2) antimetabolites, (3) mitotic 
Common Name 
Cyclophosphamide (Cytoxan) 
Chlorambucil (Leukeran) 
Busulfan 
Melphalan 
Mechlorethamine (Nitrogen mustard) 
TABLE I 
ALK.YLATING AGENT93,171 
Disease Entity 
Breast cancer, melanoma, lung cancer, 
Hodgkin's disease, lymphosarcoma, 
reticulum-cell sarcoma 
Hodgkin's disease, lymphosarcoma, 
reticulum-cell sarcoma, breast cancer 
Chronic myelogenous leukemia 
Multiple myeloma, breast cancer, 
ovarian carcinoma 
Hodgkin's disease, lymphosarcoma, 
reticulum-cell sarcoma 
w 
Common Name 
6-Azauridine triacetate 
Cytosine arabinoside (Cytosar) 
5- Fluorouracil 
6-Mercaptopurine (Purinethol) 
Methotrexate (Amethoptenn) 
Thioguanine 
TABLE II 
ANTIMETABOLITES93,171 
Disease Entity 
Choriocarcinoma and myosis fungoides 
Acute leukemia (granulocytic and 
lymphocitic) 
Breast cancer, colon cancer, ovarian 
cancer, stomach cancer 
Acute leukemia (both cases), chronic 
leukemia (granulocytic), chorio-
carcinoma 
Lymphocytic acute leukemia, breast 
cancer, choriocarcinoma, head and 
neck cancer, testicular cancer 
Granulocytic and lymphocytic acute 
leukemia 
~ 
TABLE III 
MITOTIC INHIBITORS AND RANDOM SYNTHETICS93 ,l7l 
Common Name 
TMCA (Deacetyl Colchicine L-tartrate) 
Vinblastine sulfate (Velban) 
Vincristine sulfate (Oncovin) 
Hydroxyurea (Hydrea) 
Methyl-GAG 
o,p'-DDD (l,l-Dichloro-2-(o-chlorophenyl)-2-
- - (P-chlorophenyl)-ethane) 
Procarbazine 
L-Asparaginase 
Imidazolecarboxamide 
Disease Entity 
Granulocytic acute leukemia, melanoma 
Breast cancer, choriocarcinoma, Hodgkin's 
disease, lymphosarcoma 
Lymphocytic acute leukemia, Ewing's 
sarcoma, Hodgkin's disease, lymphosarcoma, 
neuroblastoma, reticulum-cell sarcoma, 
Wilm's tumor, rhabdomyosarcoma 
Granulocytic chronic leukemia, melanoma 
Granulocytic acute leukemia 
Adrenal cancer 
Hodgkin's disease 
Lymphocytic acute leukemia 
Melanoma 
Vl 
Common Name 
Bleomycin 
Daunomycin (Daunorubicin) · 
Mithramycin (Mithracin) 
Mitomycin C 
Streptozotocin 
Actinomycin D (Dactinomycin) 
Adriamycin 
TABLE IV 
ANTIBIOTICS93,171 
Disease Entity 
Head and neck cancer, Hodgkin's disease 
lymphosarcoma 
Granulocytic and lymphocytic acute 
leukemia 
Testicular cancer 
Osteogenic sarcoma 
Pancreatic islet cell tumors 
Choriocarcinoma, Ewing's sarcoma, Wilm's 
tumor, testicular cancer, melanoma 
Ewing's sarcoma, Hodgkin's disease, lung 
cancer, lymphosarcoma, neuroblastoma, 
osteogenic sarcoma 
CJ'\ 
Common Name 
Cortisone 
Hydrocortisone 
Prednisolone 
Prednisone 
Delta-1-testololactone 
Fluoxymesterone 
Testosterone propionate 
Diethylstilbestrol 
Ethinylestradiol 
ACTH 
Progesterone 
TABLE V 
HORMONAL AGENTS93,171 
Disease Entity 
Lymphocytic acute leukemia, breast cancer, 
lymphosarcoma 
Lymphocytic acute leukemia, breast cancer, 
lymphosarcoma 
Lymphocytic acute leukemia, breast cancer, 
lymphosarcoma 
Lymphocytic acute leukemia, lymphocytic 
chronic leukemia, breast cancer, lympho-
sarcoma, recticulum cell sarcoma 
Breast cancer 
Breast cancer 
Breast cancer 
Breast cancer, prostatic cancer 
Breast cancer, prostatic cancer 
Lymphocytic acute leukemia 
Endometrial cancer 
........ 
8 
inhibitors, (4) antibiotics, (5) hormonal agents, and (6) random 
synthetics. 
Many mechanisms have been proposed to explain the different stages 
L! . . .. • 171 
0.1: drug action •. But to date, no single mechanism can embrace all 
known observations and results for any of those drugs. There appears to 
be a connnon mechanism of action in drugs categorized under alkylating 
agents. Many of these drugs possess the general formula indicated 
below: 171 
CH2-CH2-Cl 
I 
R-N: 
I 
CH2 -CH2--Cl 
Reaction may be with nucleophilic centers within the cell including a 
number of biologically important groups, e.g., phosphate, amino, 
sulfhydryl, hydroxyl, imidazole and carboxyl. This may take place 
through formation of the highly reactive, electrophilic ethylenimonium 
derivative from the teritary amine in neutral or alkaline aqueous solu-
171 tion according to the following general reaction: 
Efforts to identify metabolites responsible for the antitumor 
'effects of many drugs are ~urrently in progress. If successful, such 
data could lead to the ultimate development of anticancer agents with a 
high therapeutic index. 
Undesirable side effects of drugs usually occur which may be 
.b d . . h f 93,171 attr1 ute to cytotox1c1ty t ereo . Anorexia, nausea, vomiting, 
alopecia, dizziness, erythema, diarrhea, anemia, glossitis, leucopenia 
and thrombocytopenia are occasionally observed with some of the anti~ 
d . 93,171 cancer rugs. Often on withdrawal of drugs the changes are 
93 171 
reversible and the patients recover completely. ' 
h h b . d b 1 ... 1 ·11 252 t e c anges may e accompanie y c 1n1ca i ness. 
In some cases 
A well known 
example is adriamycin, which has a broad spectrum of clinical 
activity. 252 Unfortunately, it can have a unique toxic effect and can 
cause damage to the heart with fatal cardiac failure. Obviously this 
9 
situation reduces the length of time which the drug may be administered. 
Heterosteroids and Model Systems 
Biological activity of certain compounds may he ascribed to 
particular functionalities already built into the system. Some com-
109 176 155 156 pounds containing a pyrazole, · ' a pyrazolone, ' or an 
. 1 53,63,174,229 f . 1. ( d . d . . 215,250 f 1soxazo e unctiona ity an certain erivat1ves o 
urea and thiourea) have been found to be biologically active. 
178 Since it has been reported that specific enzymes are capable of 
using many drugs, pesticides, and other chemicals which contain sulfur 
as substrates, we considered it worthwhile to incorporate a sulfur atom 
into certain heterocyclic ring systems. Sulfur when present in certain 
heterocyclic ring systems is susceptible to enzymic oxidation to 
lf 'd 178 Ph h' . (1) . .di d178 . h. . h su oxi e. enot 1az1ne · 1s oxi ze in t is manner in t e 
,-J 
rat, as are the drugs promazine (2) and chlorpromazine (3). Methylene 
.-..ii ,...._,J 
Blue (4) is not only partly converted to its sulfoxide in animal tissues 
but is also metabolized to the sulfone. 178 
10 
( CH2)3NC CH 3)2 · HCl 
@(~:@ 
1 
-w 
3 
5 6 
-
A number of organophosphorus compounds in connnon use as pesticides 
. hi h 122 contain t oet er groups. In both plants and animals these chemicals 
are often susceptible to oxidation to the sulfoxide and sulfone. 122 
Methisazone (5) is one of a group of derivatives of isatin-S-thiosemi-
r-.J 
b h · · 1 . . 250 H d (6) . car azone t at possesses antivira activity. y roxyurea is an 
~ 
antitumor agent of simple structure that causes a relatively specific 
215 inhibition of DNA synthesis. 
The [3,2-~]-2'-phenylpyrazole of 9a-fluoro-6-16a-dimethyl-~6-
hydrocortisone (7) is clai~ed to be a very potent antiinflammatory 
,-.,..> 
11 
steroid known--over 2,000 times as powerful as hydrocortisone itself. 176 
178-Hydroxy-17a-methylandrostano[3,2-~]pyrazole (8) possess a very 
__, 
favorable anabolic-to-androgenic activity ratio and has undergone 
2 
clinical study. 38-Hydroxyandrostano[l7,16-~]pyrazole (9) exhibits an 
,......_., 
antiovulatory activity one-fifth of that observed for norethisterone 
when administered orally in rats. 2 Sulfapyrazoles such as Orisul (10) 
,.-..> 
h d 1 d b . . . . . . 4,104,220 s owe a pro onge acteriostatic action in vivo. 
A search for more effective pyrazolinones as drugs was stimulated 
by the discovery of 2,3-dimethyl-l-phenyl-3-pyrazolin-5-one by Knorr 
in 1883. 155 Pyrazolinones have been used in medicine as analgesics156 
d . . 156 an antipyretics. 
Medicinal applications of certain isoxazoles have been investigated 
v 
since 1955 with the discovery of oxamycin. 118 Incorporation of an 
isoxazole functionality into sulfa drugs has produced strong activity 
in vivo against gram-positive and gram-negative bacteria. 229 3,4-
Dimethyl-5-sulfanilamidoisoxazole (Gantrisin) is an example in this 
229 
class of drugs. It has been proven that [2,3-d]isoxazole 11 shows 
- ~ 
9.7 times as much anabolic activity as methyltestosterone, its precur-
sor, while the androgenic activity was only 0.24 times:63 The other 
isomer, [3,2-c]isoxazole 12, was found to be a strong anabolic agent. 
- ~ 
It is surprising that these compounds are devoid of estrogenic 
. . 
63 l'k h d' 1 ( . h d activity, un i e t e correspon ing pyrazo es compare wit compoun 
8). Compounds 13 and 14, two isoxazolosteroids, have exhibited anti-
,...J ~ ~ 
. . 53 tumor activity. 
i 
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The chemistry and synthesis of pyrazoles and isoxazoles have been 
knd-wn to chemists since 1885. Both of these functionalities can easily 
be introduced to the corresponding 2-hydroxymethylene ketones. Benzo-
[b]thiochromano[3,4-d]isoxazole (15), benzo[h]thiochrotnano[4,3-c]-
- ~ - -
isoxazole (16), and l-hydroxy~3H-benzo[h]thiochromano[4,3-c]pyrazole 
~ - . - -
(17) have been prepared 
,-_.I 
from the 2-hydroxymethyiene compound 18 
. __, 
(Scheme 1). 4-Methyl-7-methoxy-10,ll-dihydro-2~-pyrazalo[3,4-!]-
phenanthridirte (21) was prepared from the corresponding a-hydroxy-
__, 
methylene ketone 22 (Scheme 2). 
r-J 
S 1 d . f ibl t t f t" 5,22,39,42,43,44,45, pectra stu ies o poss e au omer orma ion · 
50,5.2 ,62 '90, 97'99,105 ,106 ,113,135 ,137 ,159 ,169,185'186 ,248 ,249 in subs ti-
tuted and unsubstituted pyrazoles have been reported, and the structures 
were well characterized. A study of the spectra and acidity of unsub-
239 
stituted pyrazoles and pyrazolones have been recently reported. 
The ease with which isoxazoles can be synthesized is reflected in 
the large number of these compounds whose spectra have been 
1 d 29,30,147,148 ana yze . Apart from simple structural analysis, NMR 
. 138 
spectroscopy has been used to study isomers of isoxazoles. Since 
. 112 183 
controversy is still found in many publications ' as to the common 
existence of two isomers (and in view of much NMR data supporting two 
structures), a critical 13GMR analysis seems could very well solve this 
problem. 
Molecular Complexation in Chemotherapy 
72 The possibility of partial or complete reduction of side effects 
of one drug when used in combination with others has prompted investiga-
tions of molecular complexes. It has also been found that uptake of 
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16 
nutrients by ~· subtilis in the presence of actinomycin-D, a known anti-
. 58 
cancer drug, was greatly enhanced by the presence of an azasteroid. 
It was concluded from spectral analysis that the potentiation of 
actinomycin D may be due to an azasteroid-actinomycin-D complex (Figure 
1). 58 Results of the potentiation experiment using the hydroxy-
pyrazole 24 in combination with actinomycin D against Pseudomonas 
r..J 
fluorescens indicated that potentiation occurred and was quite pro-
nounced (Figure 2). 119 The action of polymyxin, a surface-active 
66 
antibiotic thought to cause disorganization of the cell membrane, 
proved to be greatly potentiated when used in combination with the 
hydroxypyrazole 24 (Figure 3). 119 Potentiation of the polymyxin by the ,..._, 
pyrazole 24 was observed using the gram-positive bacterium Bacillus 
,...._, 
subtilis W23. 
HO 
24 
.--
H CO 3 
25 
-
Recently an NMR investigation has been extended to study complex 
f 37 · · b · d 1 D Al D Al ormation in yitro etween vancomycin an acety - - a- - a. 
Perkins 211 has found that mucopeptide precursor molecules containing 
the terminal-D-Ala-D-Ala fragment bind strongly to the antibiotic 
vancomycin. This would be expected to interfere with bacterial cell-
wall formation and offers a possible mechanism of action for the anti-
hiotic. It was also found that the action of vancomycin was potentiated 
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19 
by the combination with methoxyimine 25 (Figure 4) against Bacillus 
__,, 
b ·1· 59 SU ti is. 
A primary goal of our research was to determine the nature of 
molecular complexes which are formed between selected anticancer drugs 
and certain heterocycles as part of a program to investigate the mode 
of action of heterocycles as potentiators of anticancer drugs, certain 
20 
structural features irt the molecules may be important. For example, the 
introduction of heteroatoms (like S, O, N, etc.) provides lone pairs of 
electrons for possible complexation sites (might act as charge transfer 
donor atoms) and for improved H-bonding potential. 
A schematic representation of the general process of molecular 
complex formation may be envisioned as: 
nticancer 
dru + 
optimum pH 
beterocyclel reterocyclel 
Since potentiators could act like donors, one might select an anti-
cancer agent with "acceptor properties" for complexation studies. The 
use of the Pariser-Parr-Pople approximation,*172 consideration of cost 
and easy availability of anticancer drugs, and finally reasons of 
solubility have prompted us to choose 5-fluorouracil as the acceptor 
candidate for complexation studies. 
*The use of PPP approximation for TI-electron density has led us to 
a major prediction concerning the ionization potentials of the nucleic 
bases. According to this approximation the increasing order of the 
TI-ionization potentials should be in the following order for the hetero-
cycles: Guanine< Adenine< Cytosine< Thymine< Uracil. 
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Actually, the existertce of intensely colored, molecular complek.es 
197 has been known to chemists for many yea.rs. Still the very nature of 
1 1 b d . 1 1 1 i ' f' d. llO intermo ecu ar on s in mo ecu ar comp exes s a matt~r o ispute. 
But the tendency to accept the formation of weak complexes has beert 
gaining momentum in recent years owing to the possible existence of 
h 1 . b" 1 . 1 212 sue comp exes in io ogica systems. 
As a first approximation, it may be logical to assume that the 
major contribution is displacement of electron density from the donor to 
110 the acceptor molecule. B h 1 b d 1 . . 46.49 . h ut t e ow on comp ex energies in t e 
TI complexes have led to the suggestion that formation of very weakly 
bonded complexes may be due to van der Waals attractive forces, polar-
ization forces, and dipole-dipole interactions and not necessarily to 
110 
charge transfer. Actually the extent of charge transfer, and hence 
I I 
the strength of binding between the components in the ground state, may 
be determinedl3 by the ionization potential of the donor and the 
electron affinity of the acceptor. 
Th 1 . f . . 19 5 f 1 1 1 f h d · e c assi ication o mo ecu ar comp exes o t e oner-acceptor 
type is ba.sed upon the type of orbitals involved in bond formation. 
Accordingly, the donor molecule may be divided structurally into three 
categories--n, ~and TI and the acceptors into v, o and TI. At least, 
nine different types of donor-acceptor complexes are poss~ble. They 
are shown below with general examples in brackets. 
(1) n-v [R20·BX3] (2) n-TI [R20·Ar] 
(3) n-o [R20·I2] (4) TI-v [Ar·BX3 ] 
(S) TI-o [Ar·I2 ] (6) TI-TI [Ar•Ar] 
(7) o-v [RX·BX3] (8) o-cr [RX·I 2] 
(9) o-TI [RX·Ar] 
23 
Arn . h . . . . 204 h b d 1 'th ong t ese, extensive investigations ave een ma e on y wi 
respect to complexes of type TI-TI and TI-cr. 
b 1 . 14,54,153,196,205,208 h f A num er of genera reviews on c arge-trans er 
complexes have been published as well as others more specifically con-
9, 10, ll, 12, 13 ,14 . 157 b' 
cerned with energetics, spectra, reactions io-
h . 1 . l' . 234 d d 'th . 11 c emica imp ications, . an many scattere papers wi misce aneous 
d 61,65,70,71,83,104,128,129,130,131,132,145,154,160,162,163,164,207, ata. 
230,233,240,241 The reader is referred to these for details of other 
properties of molecular complexes. Only very pertinent publications 
will be discussed here. 
A donor-acceptor (DA) complex can also form by electrostatic 
attraction between an electron-rich donor (D) and electron-poor.acceptor 
(A); the species can also be called a TI complex. 
D + A ~ DA ;:= D +A -
Additional stabilization of the complex can occur as a result of a minor 
amount of delocalization of one or more electrons over several 
t 31,158 a oms. An example of a charge transfer is derived from N-
methylpyridinium iodide (26); the electrostatic complex is depicted by 
,..-
(27) and the minor amount of charge transfer structure by (28). 
,......, ,...._, 
@ + I ~ ~ I ~ @-- I " " ~ + N -t I 
CH3 CH3 CH3 
26 27 28 
-
__, 
-
Another example of this type is benzene-iodine complex as pictured 
below. A very interesting example in this category is that involving 
24 
then cloud of the vinyl group of Q-allylphenol (29), which can act as 
an electron donor to the hydroxylic hydrogen as mentioned. 41 
29 ,', 
-
The forces between an enzyme and an inhibitor or substrate that 
cause complex formation can be divided into two generalized classes: 41 
L Complexes between electron donors and electron acceptors. 
2. Nonpolar interactions of the van der Waals and hydrophobic 
bonding type. 41 
Usually there will be more than one interaction between an enzyme and 
its substrate. 
Hydrogen bonding is perhaps one of the.most significant secondary 
interactions that operates to alter the physical properties and/or 
maintain the integrity of specific confi~uration of biologically active 
. 243 
compounds. In biological systems as in others the most important 
hydrogen-bonding groups are OH and NH. Sulfhydryl groups do not often 
participate very effectively in hydrogen bonding, though they are cap-
able of f'brming such bonds. 102 The possible donor groups on the 
enzyme for a hydrogen bond to an electron-deficient hydrogen on an 
inhibitor are41 (a) the nitrogen lone electron.pair on the imidazole 
ring of histidine, (b) the carboxylate anion of aspartate and glutamate, 
(c) the amide carbonyl group of asparagine, glutamine, and the poly-
amide backbone, (d) the hydroxylic oxygen of serine, threonine, and 
tyrosine, (e) the lone sulfur electron pair of methionine and cystine, 
and (f) the TI-electron system of the indole ring of tryptophan. The 
possible hydrogen acceptors on a protein41 (a) the amide hydrogen of 
asparagine, glutamine, and the polyamide backbone, (b) the hydroxylic 
hydrogen of serine, threonine; and tyrosine, (c) the thiolic hydrogen 
of cystine, (d) the ring NH of tryptophan and histidine, and (e) pos-
sibly the ammonium group of arginine and lysine. 
Although molecular complexes had long attracted theoretical 
speculations from chemists, real insight into their nature was only 
achieved by Brackman33 and Mulliken194 a little ov~r a quarter-century 
25 
ago. Much information on spectroscopic and thermodynamic behavior of 
charge-transfer complexes has been collected and discussed by Briegleb48 
13 
and Andrews and Keefer. The possible role of charge-transfer com-
plexes in reactions has been examined carefully in only a few instances, 
even though such complexes are frequently postulated as intermediates. 
Information about the equilibria between free reactants and TI com-
plexes and about the structure of TI complexes, has come from many dif-
. 11 180 ferent experimental methods. ' Useful approaches have included 
. 'bl 1 ' 1 180 d ' f d ' h ' 91 PMR visi e, u travio et, an in rare spectroscopic tee niques. 
analysis has been successfully used to evaluate equilibrium constants 
in hydrogen-bonding systems 26 and should be similarly useful in TI- · 
complex equilibria since the two types of equilibria are formally the 
same. Further, NMR analysis is extremely sensitive to small changes 
in the electronic environment of a magnetic nucleus. 
26 
When a small molecule is bound to a macromolecule, its rate of 
molecular motion, particularly rotational motion, is generally 
diminished, and restrictions of this nature will be revealed by increase 
53a in the "relaxation rates" of the protons in the bound molecules. 
It is probable that the rotational freedoms of the various parts of a 
bound molecule will not be affected to the same extent, the more 
tightly attached units being more restricted than those not so directly 
involved at the site of the binding. 53a In such cases a selective 
change in correlation times can occur and can be detected by a selective 
broadening of the NMR signals in the spectrum of the bound molecule. 53a 
It seems highly probable that a meaningful interpretation of relaxation 
rate measurements can reveal the nature of molecular interaction. The 
first application of these principles to be reported in full was a 
study of the binding of benzylpenicillin (penicillin G) to bovine serum 
lb . 53a Th' . . . . 53a,100 ill d 11 h h i a um1n. is 1nvest1gat1on ustrate we t e tee n ques 
and safeguards in relaxation experiments and also showed how the results 
might be interpreted. (For details see reference 53a.) 
A kinetic model was proposed for the exchange between free and 
bound molecules (T h ) as well as for the relaxation times.s3a,lOO 
exc ange 
Three possible cases, depending on the rate of exchange between the 
. h b d' . . i h d 53a,100 states, can t en e 1st1ngu s e • 
Rate: 
or 
1 
-----< T 
exchange 
Very slow slow fast 
(1) 
27 
(1 J ·. 1 ~i2 )bound - < ~ T free T 2 exchange (2) 
Rate: Very slow slow fast 
or 
(i2)free < (i Jbound < T ~ exc ange (3) 
Rate: slow fast very fast 
Equations (1) and (2) probably do not apply. If we assume equation (3) 
is valid, each relaxation process will have contributions from both 
free and bound species, and the time-averaged relaxation rate of the 
two forms may be given by: 
1 
-= (1) (1) B- + 1-B -T2 bound ( ) T2 free (4) 
(5) 
where B is the fraction of the total penicillin bound. 
The problem is to.obtain (i2)bound experimentally. Let P and A be 
the total penicillin and albumin concentrations respectively, and 
assume that there are n noninteracting binding sites on each protein 
molecule. Then, on the basis of the law of mass action, 
K = [unbound penicillin][unbound sites] 
PB 
K P(l - B)(nA - PB) PB (6) 
28 
and on rearranging 
p K + nA B - 1 B (7) 
To evaluate B [and hence (iJbound from equation (5)] and K, P and A 
must be plotted under conditions where B is a constant. P and A values 
which satisfy this requirement are established by usirig various known 
combinations of P and A concentrations. 
114 Hammes and Tallman · used a treatment similar to that of Fischer 
100 
and Jardetzky for the calculations of binding constants from relaxa-
tion time data. The fraction of bound epinephrine, a, can be computed 
from the expression: (L-epinephrine-phosphatidylserine complex) 
l/T2b 
where 1 is the reciprocal spin-spin relaxation time of the free 
T2f 
1 
epinephrine, is the reciprocal relaxation time of the complexed 
T2b 
(8) 
epinephrine, and ~1- is the reciprocal relaxation time .of a mixture of 
T2m 
epinephrine and phosphatidylserine of known composition. The value 
1 
of ~- can be obtained by measuring the line width of the appropriate 
T2f 
resonance signal of free epinephrine. The exact shape of this curv.e 
depends on the stoichiometry and stability of the complex formed. How-
ever, over the range of concentrations accessible in this study, the 
data appeared to approximate a straight line. The results of calcula-
tions of K, using different resonance signals and L-epinephrine 
29 
( 1 1 . . ) ·1 bl 114 concentrations and assuming a : interaction are avai a e. 
L-epinephrirte + phosphatidylserine complex 
A most common approach for determination of equilibrium constants 
is that frequently referred to as the Beneai-Hildebrand method. 23 , 24 
Consider the equilibrium 
A+D AD 
where A and D represent acceptor and donor molecules, respectively, and 
AD represents the 1T-molecular complex. This method takes advantage of 
the fact that most 1T complexes have a new absorption band in the 
visible or ultraviolet region of the spectrum. From an appropriate 
plot of observed optical density versus donoi concentration, the 
equilibrium quotient and molar absorbancy index of the complex can be 
calculated. 
117 Hanna and Ashbaugh derived an expression analogous to the 
Benesi-Hildebrand equation for use with NMR data. Consider the chemical 
179 
shift of protons on A molecules which are undergoing rapid exchange 
between the complexed and the free condition. Following treatments of 
. 21 136 data used in NMR studies of hydrogen-bonding equilibriums ' it can 
be shown that 
foAobsd - oAo) = 1 !D~ Q (oAAD - oA ) ~ D o (9) 
where oA0 is the shift of acceptor protons in uncomplexed form, oAobsd 
is the observed shift of acceptor protons in complexing media, oAAD is 
30 
, . 
. 1. 
:the shift of the acceptor protons in the pure complex, and ~ is th._ 
concentration of donor on some arbitrary scale. Equation (9) requires 
that ~D >> ~A. It further assumes that the solutions are ideal, in 
YAD 
which Q = K, or that the quotient -- remains constant over the range 
YAYD 
of solutions studied. Defining f:i.A b d = oAb d - oA and f:i.AAD .. = oAAD -0 s 0 s 0 
oA , equation (9) becomes 
. 0 
Writing equation (10) in reciprocal form gives 
1 
= 
(10) 
(11) 
Now this equation is analogous to the Benesi-Hildebrand equation except 
that the concentration of acceptor does not appear, and the shift of 
acceptor protons in pure complex replaces the molar absorbancy index of 
the complex. The first difference means that the chemical shift of 
acceptor protons does not depend on acceptor concentration as long as 
~D >> ~A. This has been strongly supported in experiments on several 
. . 115 
different types of complexes. 
When we consider non-ideality of solutions, problem of activity 
coefficients appear to play a greater role. If we assume that on 
arbitrary concentration scale, the ac;ivity coefficient YA' yD' and yAD 
appropriate to this concentration scale of the species A, D, and AD, 
YAD 
respectivelY,, are such that the quotient is not unity. The 
YAYD 
31 
equilibrium constant K may then be written: 
K = [AD] 
[A] [AD] 
This process further complicates the computation of association con-
stants. 
The primary question that arises is whether the equilibrium 
quotients derived from NMR data can be accepted with confidence or 
whether some type of solvent effect on spectra is important. This 
question is especially appropriate in view of the relatively small 
absolute value of the measured shifts. In order to explain these mat-
94 116 ters of extreme importance, two tables (Tables VI and VII) ' are 
shown. 
There are three factors 116 which argue that it is indeed the effect 
of molecular complexation that gives rise to the observed shifts. The 
first is that the size of the equilibrium constants are in the right 
order. That is, as the ionization potential of the donor becomes lower, 
h 'lib . . . 116 t e equi rium constant increases. The second is that a comparison 
with equilibrium quotients calculated from spectroscopic data115 is pos-
sible and gives good agreement in some cases. The third is that, when 
the TCNQ* (an excellent receptor) is replaced by an aromatic molecule 
116 
which is not expected to complex with a weak donor, toluene for 
example, no shift of the protons on this molecule is observed under 
specified conditions. All of these facts argue strongly against the 
observed shifts of the TCNQ protons being due to some kind of a general 
*7,7,8,8-Tetracyanoquinodimethane 
TABLE VI. 
MEASURED AND CALCULATED PROPERTIES OF ~-MOLECULAR COMPLEXES OF TCNQ AND A 
SERIES OF AROMATIC DONORS IN DIOXANE116 
Qm, 
Range of donor 
Max. !J. b dA kg. of (!J.ADA)m' ~· concentration, 0 s ' solvent/ 
-1 
m c.p.s. mole p.p.m. m.f. 
Benzene 0.468-2.15 8.6 0.061 1.28 
Toluene 0.401-2.88 12.4 0.085 1.06 
2-Xylene 0.353-2.54 13. 7 0.12 0.91 0.47 
Mesitylene 0.298-2.18 12.7 0.16 0.80 1.10 
Durene 0.207-0.967 9.3 0.33 0.67 2.7 
Pentamethylbenzene 0.056-0.457 8.0 0.55 0.59 6.2 
Hexamethylbenzene 0.100-0.295 7.1 1.15 0.56 9.7 
(!J.ADA)x' 
p.p.m. 
2.86 
1.43 
1.10 
0.67 
0.57 
w 
N 
Solvent 
CC14 
HCC13 
CH2c12 
TABLE VII 
THE MAXIMUM OBSERVED SHIFTS Eimax' THE CALCULATED SHIFTS FOR THE PURE COMPLEX llo 
(BOTH RELATIVE TO 1,3,5-TRINITROBENZENE), AND THE ASSOCIATION CONSTANTS OF 
THE COMPLEX 1,3,5-TRINITROBENZENE + N,N-DIMETHYLANILINE IN VARIOUS 
SOLVENTS AT 33.5° 
llmax 
c/sec 
42.0 
45.5 
37.5 
ti 0 
c/sec 
61.5 
76.5 
80.4 
K 
kg/mole 
3.26 
o. 72 
0.39 
K 
l./mole 
2.04 
0.45 
0.25 
w 
w 
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solvent effect but argue for formation of a molecular complex. 
Still we have to account for other factors. As evidenced from 
Table VI, the calculated equilibrium quotients and shifts of acceptor 
protons in the pure complex are dependent on the concentrations used. 
Since the quantity ~AAD is a function only of the structure of complex, 
it should be independent of the concentration scale. In fact, the 
values of MAD determined on the model scale are different from the cor-
responding quantities determined using the mole fraction scale. A small 
shift difference of the order of ~ 1. 0 Hz is understandable; but no good 
explanation for this phenomenon has been put forth. 
In Table VII we observe that K values for charge-transfer complexes 
are very solvent-dependent. Thus, K for the complex between 
1,3,5-trinitrobenzene and !,!-dimethylaniline is 20 times as great in 
CC14 and 60 times as great in cyclohexane as in dioxane. Interest-
inglY)an optical determination of the equilibrium constant of the system 
!,!-dimethylaniline and 1,3,5-trinitrobenzene in cc14 gave K = 2.2 
9./mole, at 33.5°C, which is in good agreement with the NMR determined 
value, K = 2.04 9./mole. Unfortunately, because of solubility limita-
tions in many cases, it is very difficult to compare K values determined 
in different methods. 
The ideal system for NMR study of molecular compl'¥xes would appear 
to be the following: 
(1) Both donor and acceptor molecules should contain protons (or 
other magnetic nuclei), preferably giving a single sharp line. 
(2) Equivalent donor and acceptor concentrations should be possible 
in a common solvent. 
35 
(3) The NMR absorptions of donor or solvent should not overlap with 
the absorption of acceptor (vice versa if donor shifts are being 
studied). 
Unfortunately it is very difficult to find an expetimental system for 
which these conditions all hold. Although a new technique, 13cMR, 
offers several advantages, the need for large amounts of materials or 
else the cost of making 13c enriched compound has caused progress to be 
slow. 
Since in our investigation sulfur compounds have been used as donor 
candidates, thermodynamic and spectral properties of some sulfur com-
pounds are given in Table VIII16 ,l6l,lS9 ,zoz for the sake of comparison. 
It is evident from the data that symmetry and overlap of the donor and 
acceptor orbitals appear far to outweigh the simple criterion of the 
190 
electron affinity of the acceptor. (This again complicates the 
molecular complexation studies.) Iodine has a lower electron affinity 
than TCNE (tetracyaoneothylene), but the spatial disposition of its a 
u 
antibonding orbital is far more suitable for complexation than the 
corresponding delocalized TI-orbital of TCNE. 190 
The donor properties of sulfur, selenium, tellurium, and oxygen 
h b . . d 79 ave een investigate • The outer, lone-pair, p-orbitals of these 
atoms can be compared on the basis of size, and electron-donating 
ability as measured by gaseous ionization potentials. 79 The values 
of these parameters are listed in Table Ix. 79 
The majority of these complexes involving sulfur compounds are not 
sufficiently stable to be isolated as solids. The heats of association 
190 
are generally less than -10 Kcal/mole. 
Donor 
Thiophene 
Thianthrene 
Phenoxanthiin 
(C6H5)2S 
(C6H5)2S2 
(C6HSCH2)2S2 
(C6HSCH2)2S2 
(C6HSCH2)2S2 
c6H5scH3 
TABLE VIII 
THERMODYNAMIC AND SPECTRAL PROPERTIES OF MOLECULAR6COMPLEXEs2gF AROMATIC AND HETEROCYCLIC SULFUR COMPOUNDS AT 2s 0 cT ,101,189, 2 
Kc -ti.He 
Acceptor (Q,/mole) (kcal/mole) Solvent 
I2 0.4 octane 
I2 1.2 3.8 CC14 
I2 0.85 4.1 CC14 
I2 0.3 octane 
TCNE 1.5 CH2c1 2 
I2 601 4.8 octane 
TCNE 2.6 CH2c12 
I2 4.8 octane 
I2 9.2 6.1 CC14 w 
CJ'\ 
Atom 
0 
s 
Se 
Te 
TABLE IX 
ATOMIC RADII AND IONIZATION POTENTIALS OF GROUP VI ATOMS 79 
Atomic Radius (A 0 ) Ionization Potentials (ev) 
0.66 13.6 
1.04 10.4-
1.17 9.8 
1.37 9.0 
w 
" 
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120,121,199,235 f Scheme 3 shows three of the many reported cases . o 
molecular complex formation in solution. The proposed structures of 
these molecular complexes were deduced from NMR spectral analysis of 
the complexes and of the corresponding unbound candidates. Hatton and 
Richards120 , 121 observed that the dilution of dimethylformamide with 
benzene caused a large upfield shift of the methyl proton resonance 
trans to the carbonyl function. It was further postulated that the 
association was between the electron-deficient nitrogen atom and the 
TI-electrons in benzene. The oxygen atom comprising the negative end of 
the amide dipole is oriented as far away from the benzene ring as 
possible. 
Laszalo and Williams165 have measured the relative solvent shifts 
of methyl and methoxy protons in substituted E-benzoquinones and the 
225 
existence of the complexes ~ and ~ have been postulated. Complex 
.'E is a very good example for donor-acceptor type interaction. 
E-Fluorophenylborondichloride (35) acts like an acceptor and p-fluoro-
-
benzonitrile (36) acts like a donor candidate. 
--
A variety of physical methods, other than already discussed, has 
been used for the experimental evaluation of K. They include: 
partition of one component of the complex between two innniscible sal-
t 7.187 1 b'l't 8,9,10,35 d ven s, so u 1 1 y, an vapor pressure measurements 
. . . . 68 69 74 75 76 103 209 1nclud1ng gas 11qu1d chromatography, ' ' ' ' ' ' polar-
ography, 210'228 and kinetic measurements of the further irreversible 
chemical reactions of the components and/or the charge-transfer 
1 27, 67,182 h 1 h . 1 d 1 . 12, 28 1 . 1 comp ex. T ey a so ave 1nvo ve ca or1metry, u trav10 et 
and Vl'si'ble t 80,84,95,96,152,170,200,226,244 d . t 't spec roscopy, an in ens1 y 
measurements of infrared absorption bands, 144 • 166 , 184 , 188 ~ 216 and of 
0 
II 
1. c6H6 + (CH3)2N-C-H 
2. c6H6 + o~o 
32 
,...._,, 
3. F-@-Bc1 2 + NC-@-F 
35 36 
CH3 + 0-
'N=C/ 
CH/ I 'H 
I 3 I 
I I 
,g) 
o~ -~o 
31 
,,_.... 
...... 
/ 
~ 
(2:1 complex) 
. 33 
,,,,-... 
(or) 
CH2Cl2 -@-. 0 /Cl ~o 
~ F · B----N:C ~_rF 
"-c1 
37 
,,,...,. ·~·· 
Scheme 3 
o~o 
<§> 
(1:1 complex) 
34 
,,__, 
w 
"° 
Raman bands. It is not possible to review here the various 
techniques involved in these approaches or to detail the results which 
have been obtained. 
The inability to produce satisfactory results using single drugs 
in patients with advanced cancer naturally led to the use of drug com-
b . i 81 inat ons. 140 Though theories have been put forward to explain 
combination therapy, the mechanism of action of "drugs in combination" 
has not been totally viewed to include complexation in all cases prior 
to or in course of drug metabolism. It is not yet clear whether weak 
40 
dipole-dipole interaction, or hydrophobic interactions, or even van der 
Waals forces produce synergism or antagonism. The classic example of 
what appears to be true synergism is the combined use of penicillin and 
streptomycin in the treatment of endocarditis due to Streptococcus 
faecalis. 
One of three possible effects can be expected when drugs are used 
in combination: (1) drug indifference--that is, a result readily 
accounted for by the sum; (2) antagonism--a result less than the sum; 
and (3) synergism--a result greater than expected fr~m the sum of 
activities of the individual agents. In general, a combination of 
\ 
bacteriostatic drugs is additive; a bactericidal plus a bacteriostatic 
drug may be antagonistic; and a bactericidal plus a bactericidal drug 
h . 140 may s ow synergism. 
The use of combination drug therapy for cancer is gaining increas-
ing acceptance. This has resulted from the demonstrated effectiveness 
of multiple-drug regimens in the treatment of acute leukemia,lOl,l3l 
Hodgkin's disease82 and carcinoma of the breast. 51 Unfortunately, 
there are few guidelines that provide a rational basis for the selection 
of agents to be used in combination, since little is known of the 
factors responsible for the augmented cytotoxic effects observed when 
certain drugs are administered together. 
41 
The combination of 5-fluorouracil (5"-FU) with BCNU has been proved 
beneficial; patients do not experience diarrhea or mucocutaneous reac-
223 tions as they do with 5-FU. Nausea and vomiting were experienced 
with approximately equal frequency with all the regimens except 
223 
mitomycin C alone which showed a slight advantage. Diarrhea and 
mucocutaneous reactions were prominent in the 5-FU group, but were non-
existent with other single drugs and negligible with the drug combina-
t . 223 ion. It seems logical that proper selection of combination of drugs 
might reduce side effects of some anticancer agents. 
Since 5-fluorouracil has been selected as a major acceptor candi-
date for molecular complexation studies in our work, the chemistry and 
biological activity of this anticancer drug are given in the following 
section. 
Orotic acid (38) has been considered the precursor of the nucleic 
-
acid pyrimidines. It was found in several transplanted tumors that 
uracil (39) was incorporated into DNA to a greater extent than was 
·-
orotic acid·. 126 The structures of the important natural pyrimidines 
are shown in Figure 5. Uracil is found in RNA and not in DNA, and 
thymine (40) is present in DNA and not RNA. 167 Moreover, it is well 
,,....., 
known that thymine, an essential building block of DNA, is made by the 
attachment of the methyl group to the ring system of uracil at the 5-
position. 
It was logical to assume that the strategic substitution of a 
fluorine atom for a hydrogen atom attached to C(5) might produce a 
0 0 
HN~ HN~ O~N)COOH ~N) 
H H 
OROTIC ACID URACIL 
38 39 
,.._, 
0 0 
HN~ HN"1® 
okN) o~~ 
H H 
URACIL 5-FLUOROURACIL 
39 42 
,.....,, 
THYMINE CYTOSINE 
40 41 
,.. ... .,,. 
0 
HN~ 
okN)-
H 
THYMINE 11TRIFLUOROTHYMNE'1 
40 . 43 
,... ..... ,; 
Figure 5. Nucleic Acid Pyrimidines and Seme Model C0mp0unds 
42 
43 
, 
significant change in biological effects. For exampte, such a substitu-
tion converts acetic acid to fluoroacetic acid and thus changes salad 
dressing to a commercial rat poison. 
It was predicted that if 5-fluorouracil were to have biological 
activity it should block the attachment of the methyl group to the ring 
system of uracil, and hence block DNA synthesis. In addition, a 
fluorine atom is. very similar in size to the hydrogen atom, and so it 
seemed that 5-fluorouracil should also be incorporated into RNA. The 
schematic representation of the synthesis of 5-f luorouracil is shown 
in Scheme 4. 89 The substitution of a hydrogen atom by a very strong 
electronegative fluorine atom also increased considerably the acid 
25 
strength (pK = 8.0) compared to that of uracil (pK = 9.5). 
a a 
The first preliminary clinical report on 5-FU appeared in 1957 
and initial clinical investigations were conducted at the University of 
Wisconsin Hospitals by Drs. F. J. Ansfield and A. R. Curreri. 73 They 
reported that 5-fluorouracil had profound activity in producing 
objective responses in patients suffering from disseminated breast and 
colon cancers, and this has been amply confirmed in many other clinics. 
15 123 After 10 years of experience, Ansfield and co-workers ' clearly 
showed that the survival of recurrent breast cancer patients was 
significantly increased. 
55 It is now clear from the work of Champe and Benzer and Rosen and 
227 
co-workers that the presence of 5-FU in m-RNA can lead to a low 
frequency of translational errors as a consequence of the base-pairing 
of 5-fluorouracil with guanine as if it were cytosine (41). The bio-
chemistry of the fluorinated pyrimidines is given in considerable detail 
in a review which appeared in 1965. 127 
44 
45 46 
46 47 48 42 
Scheme 4 
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The metabolism56 ,57 , 193 of 5-fluorouracil has been well character-
ized since 1960 (Scheme 5). When 5-fluorouracil was labeled with 
radiocarbon and administered to a few cancer patients, the 2-carbon atom 
quickly appeared in the respiratory carbon dioxide and was also excreted 
. h i 56 in t e ur ne. This led to a study of the degrad~tion of 
5-fluorouracil-2-c14 in mice and men, and it was demonstrated that the 
57 
compound was degraded in a fashion exactly similar to that of uracil. 
Since carbon dioxide and urea are the end-products of the catabolism of 
5-FU-2-c14 , 57 it was necessary to prepare 5-FU-6-ci4 in order to 
determine the metabolic fate of the other moiety of the molecule. This 
was done, and it was shown that the catabolism of 5-fluorouracil takes 
place according to Scheme .5. The drug is first reduced systematically 
to dihydrofluorouracil, then hydrolyzed to a-fluoro-S-ureidopropionic 
acid (FUPA), which is converted to a-fluoro-S-guanidopropionic acid 
(FGPA), and then cleaved to a-fluoro-S-alanine(FBAL) and urea or carbon 
dioxide and ammonia. 
Meanwhile, a series of nucleoside derivatives were prepared (Figure 
6) b D hi k d k 85,125,133,134,218,245,246 y use ns y an co-wor ers. The 
· i 1 . h' 151 f h i ' f FUDR d . structure-activ ty re ations ips o t e nteraction o an its 
derivatives with the key enzymes in its mode of action were tentatively 
given and the important points are illustrated in Figure 7. 
In addition to the biochemical aspects of 5-fluorouracil, the 
molecule undergoes reactions typical of uracil. It was concluded from 
spectral investigations247 that the monoanionic form of 5-fluorouracil 
consists of an equilibrium mixture of two tautomeric forms I and II 
as shown in Scheme 6. In aqueous solution, form I, corresponding to 
dissociation the proton on the more electronegative ring nitrogen, 
0 
HN~F __. 
Ol,_N) 
H 
ol 
HN~F O~N) 
H 
! 
FUR 
l 
FURP 
l 
FUDRP 
46 
F-RNA 
t 
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.. r 
TORP 
t 
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Scheme 5 
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HO 
0 
OH OH 
FUR 
49 
,,..._,, 
OH H 
FCDR 
51 __ _, 
F 
HO 
HO 
OHH 
FUDR 
OH 
arci-FCDR 
52 
.-...-.,;' 
Figure 6. The Structures of Fluorinated Pyrimidine 
Nucleosides 
47 
0 
F 
OH H 
N-1. Necessity unknown: to be tested 
0-2. Necessary for activity 
N-3. Must be unsubstituted and with proton of correct pKa 
0-4. Probably necessary. Cannot be methylated 
C-5. Size of substituent determines incorporation into DNA or RNA and 
electron properties 
C-6. Must be unsubstituted. 6-AzaFU could not be synthesized. 
6-AZAF3TDR inactive: too acidic 
48 
H-2' H needed for DNA action, OH for RNA. 2'-Ara-hydroxyl gives 4-amino 
compounds desirable properties 
H-3' Can be blocked with methoxyl group and retains slight TdR-kinase 
and TMP-synthetase activity, but prevents nucleoside phosphorylase 
cleavage 
H-5' Must be unsubstituted. However, some S'-halo nucleosides inhibit 
TMP-kinase 
Furanose-0. Probably necessary, but not adequately tested. 
Figure 7. Structure-Activity Relationships of the Interaction of 
5-Fluoro-2Ldeoxyuridine and Its Derivatives with the 
Key Enzymes Involved in Its Mode of Action 
49 
I JI 
42 53 54 
,,, .. ,,. ,..,_ - •":,·.-· ! SOCl2 
Cl NH2 
N:JF NH3., N5F o.lN I 0.lN 
H H 
55 56 
-~ ~ .. ---. 
Scheme 6 
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comprises 63% of the mixture, but form II is predominant in solvents of 
lower dielectric constant. 
The presence of the fluorine at C(5) increases the susceptibility 
of the 4-position to nucleophilic attack as compared to attack at C(2). 
Preferential reactions at the 4-position are partially illustrated in 
Sh 6 d 7 20,87~88,242 Th h . d t' f 1 c eme an • e synt es1s an tes ing o severa 
derivatives of 5-FU were the result of anticancer properties possessed 
by 5-Fu. 124 
51 
Scheme 7 
CHAPTER II 
RESULTS AND DISCUSSION 
The results of this work are divided into three parts. Synthesis 
of pyrazoles 65, 66, 67, 81, and 85, isoxazoles 68, 84, 87, and 88, 
,,,,.._ ~ """"' ~ ·"""" ,,,,,,.,,,. ......... ......... .......... 
pyrazol-3-ones 79 and 83, and sulfones 70, 71, 72, and 73 constitutes 
"""""".,,...,,, ............ ~,,.,_. """"-" 
68 
---
65 R=H· 66 R = . I 67 R = <S}-QCH3 
\ 
N-0 
NI 
I . 
® 
71 72 
_.....,.. 
--
0 
NOH if,)H 
73 74 75 
.........,,.. ............ 
........... 
52 
53 
84 85 
-
86 
--
~co 
87 88 
77 
,?2 .R = CH3 
~ R = H 
83 
"'"'-"' 
~ R = CH 3 
82 R = H · 
---
54 
55 
the first part. A second study was concerned with a rather comprehen-
sive PMR and UV spectral analysis of hydroxy pyrazol'-3-on~ 80. This was 
'; ._ 
considered neces.sary in order to determine whether tautomeric forms 
might exist under several conditions of pH. 13 ' A CMR study was also 
initiated to distinguish the isomeric nature of structures 87 and 88. 
0 OH OH 
HO 
80 
,....._, 
87 
~ 
239 The PMR study has been published in part. 
88 
The third and final area of concentration concerned the study of 
complexation between selected heterocycles and certain acceptor candi-
dates, notably 5-fluorouracil, 1,3,5-trinitrobenzene, 4-flourophenyl-
acetonitrile, and 3,4-dihydroxybenzoic acid. Both ultraviolet and 
NMR spectral analyses were performed to examine the structure of the 
complex in solution. 
A careful NMR (Table XI) and mass spectral analysis supported the 
proposed structure of each of the new compounds. Rather than obtain 
TABLE X 
PERCENTAGE YIELDS, AND MELTING POINTS OF STARTING MATERIALS, 
INTERMEDIATES, AND PRODUCTS 
Compound Name 
Thiochroman-4-one 
2(Hydroxymethylene)thiochroman-
4_;.one 
4H[l]Benzothiopyrano[3,4-~]isoxazole 
1,4-Dihydro[l]benzothiopyrano[4,3-£]-
pyrazole 
1,4-Dihydro-1-phenyl[l]benzothiopyrano:... 
[4,3-~]pyrazole 
1,4-Dihydro-l-(p-methoxyphenyl)-[1]-
benzothiopyrano [4,3-~]pyrazole 
Cpd. m.p.' oc 
90 28-30 
.-..I 
94 
--
68 71-73 
.--
65 168.5-170 
,._., 
66 169-171 
67 145-146 
r-.J 
Yield, % 
87.5 
84.3 
93.8 
88.7 
29.0 
U1 
(j\ 
Compound Name 
4H-[l]benzothiopyrano[3,4-d]isoxazole-
-5,5-dioxide -
1,4-Dihydro[l]benzothiopyrano[4,3-c]-
pyrazole-5,5-dioxide -
1,4-Dihydro-l-phenyl[l]benzothio-
pyrano [4,3-~]pyrazole-2,5,5-trioxide 
Thiochroman-4-one-1,1-dioxide 
1-[4,0xothiochroman-3-yl)-methylene]-
2-thiourea 
6-Methoxy-1-tetralone 
2-Hydroxymethylene-6-methoxy-1-
tetralone 
TABLE X (Continued) 
Cpd. 
72 
----
70 
71 
,,........ 
73 
___, 
78 
89 
,.....__. 
93 
.-._s 
m.p., °C 
170-172 
249-250 
211-212 
131-133 
184-186 
66-68 
Yield, % 
94.8 
64.4 
99.8 
65.7 
31.4 
95.7 V1 
-...J 
Compound Name 
[(1,2,3,4-Tetrahydro-6-methoxy-l-
oxo-2-naphthyl)methylene]urea 
l-[1,2,3,4-Tetrahydro-6-methoxy-l-
oxo-2-naphthyl)methylene]-2-
thiourea 
6-Methoxy-2-methyl-2-carbomethoxy-
l-oxo-l, 2, 3, 4-tetrahydronaphthalene 
2,3a,4,5-Tetrahydro-3a-methyl-7-
methoxy-3~-benz [~]indazole-3-
one 
2,10,11,lla-Tetrahydro-7-methoxy-
lla~methyl-lH-phenanthro[l,2-c]-
pyrazol-1-one -
4,5-Dioydro-7-methoxynaphth[2,l-~]­
isoxazole 
TABLE X (Continued) 
Cpd. 
76 
-~ 
77 
97 
,_,_ 
79 
,,_,_, 
83 
·-
87 
,......,,. 
m.p., oc 
235-237 
225-227 
91-92. 5 
218-219 
258-260 
59-61 
Yield, % 
83.2 
99.3 
82.0 
90.5 
70.6 
88.0 
Vl 
00 
Compound Name 
Thiochroman-4-one oxime 
2(Hydroxymethylene)2-methoxybenzo-
suberone 
1,4,5,6-Tetrahydro-8-methoxybenzo-
[6, 7]cyclohepta[l,2-~]pyrazole 
5,6-Dihydro-8-methoxy-4H-benzo-
[3,4]cyclohepta[l,2-~]isoxazole 
2(Hydroxymethylene)6-methoxy-l-
··indanone 
2(Hydroxymethylene)5,6-dimethoxy-
1-indanone 
N-methyl-6-methoxy-1-tetralone imine 
TABLE X (Continued) 
Cpd. 
74 
96 
~ 
85 
....... 
84 
__. 
95 
98 
86 
,...._ 
m.p., °C 
. 98-100 
101-103 
52-53 
149-150 
151 
53-55 
Yield, % 
91. 7 
95.9 
62.9 
81.6 
94.0 
96.1 
97.9 
Vt 
\0 
60 
elemental analyses on each compound, the molecular ion (~) was peak 
matched via mass spectral analysis. Percentage yields and melting 
points of starting materials, isolated intermediates, and products are 
found in Table X. The significance of these compounds as chemother-
apeutic agents is of special interest in view of the biological activ-
ities found in compounds possessing similar functionalities (ref er to 
Chapter I). 
Synthetic Results 
In the course of this investigation, several key starting materials 
were required, namely the 1-tetralone ~~), thiochromanone ~' the 
indanone 91, and the benzosuberone 92. Treatment of ketone 89, 90> 91, 
""-"" """'"'~ ...,_,.... 
or 92 with ethyl formate in the presence of sodium methoxide resulted in 
/V 
0 
89 90 
-- -
0 
92 
'"'--' 
TABLE XI 
NMR ANALYSIS OF STARTING MATERIALS, INTERMEDIATES, AND PRODUCTS 
Structure Cpd. Plate Solvent o (p .p .m. )a Integr. 
90 DCC13 2. 86 (t) 2 
......... 
3.17 (t) 2 
7.00-7134 (m) 3 
8.06 (d) 1 
(d) 0. OO (a) ( ) 
c (bl (c) 
(c) 
HO 94 DCC13 3.59 (s) 2 0 -i 
7.04-7.34 (m) 3 
7.94 (d) 1 
(c) 8.30 (s) 1 
Assignments 
CR2 (a) 
CR2 (b) 
ArR (c) 
ArR (d) 
CH2 (b) 
ArH (c) 
ArH (c) 
C=CH (e) 
°' ...... 
°' N 
Structure Cpd. 
66 
-(b) ,. _ '\ 
- - -
.. (c) 
- - - - -· - -(c) 
(c) \') \_ll} 
67 
....... 
-
--- .... ..-(c) 
(c) -
- ' , . DI (h) 
(c) Y 
OCH 3 (j) 
TABLE XI (Continued) 
Plate Solvent o (p.p.m. )a Integr. 
DCC13 3. 90 (s) 2 
6.82-7.17 (m) 3 
7. 41 (s) 6 
7.56 (s) 1 
DCC13 3.83 (s) 3 
3.88 (s) 2 
6.82-7.50 (m) 9 
Assignments 
CH2 (b) 
ArH (c) 
ArH (d) and 
(h) 
N=Cli (e) 
OCH3 (j) 
CH2 (b) 
ArH (h), 
(c), (d) 
and (e) 
°' w
TABLE XI (Continued) 
71 aee13 4.41 (s) 2 CH2 (b) .,...._ 
(g)r"Y I, A 6.84-6.94 (m) 1 ArH (d) 
7.25-7.47 (m) 7 ArH (c) 
(c) '-..../" '"'' I() I,, , and (h) 
7.70 (s) 1 N=C!! (e) 
0\ 
.j::'-
TABLE XI (Continued) 
Structure Cpd. Plate Solvent o (p.p.m.)a Integr. Assignments 
71 8.01-8.12 (m) 1 Arff (g) 
"""' 
(b) 73 DCC13 3.36 (t) 2 CH2 (a) 
~ (a) 3.66 (t) 2 CH2 (b) (d)©::O 7.60-7.90 (m) 2 ArH (c) 
(c) Q (d) 7.92-8.17 (m) 2 ArH (d) 
(c) 
76 DMSO-Q.6 2.57-2.70 (m) 2 CH2 (b) ,._ 
0 ( ) 0 (s) 2.84 (t) 2 CH2 (c) ( ) e II 
a.%'.'NCNH 
'?" H 2Ci) 3.36 (s) 2. NH2 (i) H3CO~ Cb) Ci) 3.83 (s) 3 CH3 (k) 
(k) (d) (c) 6.82-7.00 (m) 2.5 ArH (d) and 
0 
II 
-C-C!! (a) 
7.80-7.90 1 ArH (f) 
°' V1 
TABLE XI (Continued) 
Structure Cpd. Plate Solvent o (p.p.m.)a Integr. Assignments 
76 [Absorption at 6.38 (s), 7.44 (s), 8.10 
............. 
(s), 9.90 (d), and 10.84 (d) may be small 
contributions from different tautomeric 
forms; all together they correspond to 
1.5 protons and thus total number of 
protons was found to be 14, which was the 
expected value.] 
77 DMSO-g6 2.60-2.80 (m) 2 CH2 (b) 
0 s (s) --(e) II 2.80-3.02 (bd) 2 CH2 (c) 
NCNH2 
2 NH2 (i) H (i) Ci) 3.32 (s) 
H3C0~(b) 
(k) (d) (c) 
3.84 (s) 3 CH3 (k) 
6.84-7.00 (m) 2.5 ArH (d) and 
0 
-c-cg (a) 
7.84 (bd) 1 ArH (d) 
"' 
"' 
TABLE XI (Continued) 
Structure Cpd. Plate Solvent 
77 
......... 
78 DMSO-g6 
0 S (s) ( ) (i) II 
Cc) ~NCNH2Ci> 
H 
(c) l '-.../A r- ,) r'L\ (i) 
(c) 
a o (p.p.m.) 
7.93 (s) 
8.67 (bs) 
Integr. 
1 
0.5 
Assignments 
N=C!! (e) 
SH (j) 
8.43 (d), 9.83 (d), and 11.78 (d) may be 
small contributions from different 
tautomeric structures. 
2.80-3.80 (vb) 1 NH (i) 
3.84-4.09 (s and d) 2 CH2 (b) 
7.20-7.57 (m) 3 ArH (c) 
7.92-8.50 (m) 2.5 ArH (d), 
N=CJ;J (e) 
and 
0 ii 
-C-CH (a) 
8.90 (bs) 0.8 SH (j) 
[10. 20-10. 32 (bd) and 11.60-11. 74 (bd) may 
be small contributions (0.8 proton) from: 
"' -..J 
TABLE XI (Continued) 
Structure Cpd. Plate Solvent cS (p.p.m.)a 
78 s SH (f) 
N-C N=C 
H(i) 
and 
92 DGC13 1. 70-1. 97 (m) ,......__ 
2.70 (t) 
0 2.90 (t) 
\..l (a) 
3.83 (s) 
(b) 6.70 (d) H3CO~ (b) 6.80 (dd) (k) (d) (c) 
7.78 (d) 
Integr. 
s 
; H2N-C 
4 
2 
2 
3 
1 
1 
1 
Assignments 
SH (f) 
NH=G 
etc.] 
CH2-cH2 (b) 
GH2 (c) 
CH2 (a) 
O-CH3 (k) 
ArH (d) 
ArH (g) 
ArH (f) 
(j'\ 
CXl 
Structure 
H3CO 
(k) 
0 
(d) (c) 
(c) (b) 
H CO i - ~ \J..J 3 
(It) : (d) 
Cpd. 
96 
-
(e) 
(b) 
85 
,..._ 
TABLE XI (Continued) 
Plate Solvent o (p.p.m.) a 
DCC13 1. 76-2. 20 (m) 
2.62 (m) 
.J.78 (s) 
6.70 (d) 
6.80 (dd) 
7.56 (d) 
7.94 (s) 
DCC13 1.77-2.18 (m) 
2.64-2.92 (m) 
3.78 (s) 
6.62-6.84 (m) 
7.41 (s) 
7.64 (d) 
10.50-11.02 (bs) 
Integr. Assignments 
4 CH2--CH2 (b) 
2 CH2 (c) 
3 O-CH3 (k) 
1 ArH (d) 
1 ArH (g) 
1 ArH (f) 
1 C=Cfi (e) 
2 CH2 (c) 
4 CH2--C--CH2(b) 
3 O-CH3 (k) 
2 ArH (d) 
1 N=C!! (e) 
1 ArH (f) 
1 NH (i) 
"' l.O 
Structure 
H3CO 
(k) 
(c) (b) 
(d) 
TABLE XI (Continued) 
Cpd. Plate Solvent 
84 DCC13 ,,..,._. 
. a 
o (p.p.m.) Integr • Assignments 
• 
1. 96 (q) 2 CH2 (c) 
2.42-3.00 (m) 4 CH2-C-CH2 (b) 
3.77 (s) 3 0-CH 3 
6 • 5 6-6 • 9 2 (m) 2 ArH (d) 
7 .83 (d) 1 ArH (f) 
8.06 (s) 1 N=CH (e) 
Structure 
H3CO 
(k) (d) (c) 
(b) 
H co~-/ \.L) 3 
(k) (d) 
(i) 
HO 
(e) 
TABLE XI (Continued) 
Cpd. Plate Solvent 
93 DCC13 
87 DCC13 ...... 
. o (p.p.m.) a Integr. Assignments 
-
2.54 (t) 2 CH2 (c) 
2.87 (t) 2 CH2 (b) 
3.84 (s) 3 OCH3 (k) 
6.72 (d) 1 ArH (d) 
6. 84 (dd) 1 ArH (g) 
7.91-7.98 (m) 1 ArH (f) 
14.40-14.76 (bs) 1 C=COH (i) 
2.63-2.82 (t) 2 CH2 (c) 
2.84-3.10 (t) 2 CH2 (b) 
3.83 (s) 3 OCH3 (k) 
6. 77-6 . 90 (m) 2 ArH (d) 
7.56-7.67 (m) 1 ArH (f) 
8.11 (s) 1 N=C!! (e) 
....... 
..... 
TABLE XI (Continued) 
Structure Cpd. Plate Solvent a o (p.p.m.) . Integr. Assignments 
88 DCC13 2.54-2.98 (m) 4 CH2-cH2 (b) ;---
(b) (e) 3.75 (s) 3 OCH3 (k) 
6.51-6.90 (m) 2 ArH (d) 
7.84 (d) 1 ArH (f) 
H3CO~<f) 8.05 (s) 1 N=C!! (e) 
(k) (d) 
86 DCC13 1. 92 (q) 2 GH2 (b) 
.......... 
2.53 (t) 2 CH2 (c) 
NCH3 
(e) 2. 77 (t) 2 CH2 (a) 
(g) ,/"" ,.-.... ~ """' (a) 3.27 (s) 3 N-CH3 (1) 
H 3CO~(b) 3.79 (s) 3 OCH3 (k) 
(k) (d) (c) 6.61 (d) 1 ArH (d) 
6.78 (dd) 1 ArH (g) 
8.04 (d) 1 ArH (f) 
..... 
N 
TABLE XI (Continued) 
Structure Cpd. Plate Solvent ·a o (p.p.m.) Integr. Assigrunents 
134 DCC13 2.64 (t) 2 CH2 (b) 
,_....-
3.01 (t) 2 CH2 (a) 
(b) (a) 3.89 (s) 3 OCH3 (k) 
or (m) 
b 
3.93 (s) 3 OCH3 (k) 
H3CO~ ca) or (m) 
6.87 (s) 1 ArH (c) (k) OCH3 
(m) 7.16 (s) 1 ArH (d) 
98 DMS0-~6 ,.._ 3.51 (s) 2 CH2 (b) 
(i) 3.84 (s) 3 OCH3 (k) 
or (m) 
0 
3.89 (s) 3 OCH3 (k) 
H3CQ.l. '-" J r.n or (m) 
I 
(k) OCH 3 5.51 (bs) 1 OH (i) 
(m) 7.10 (s) 1 ArH (c) 
7.16 (s) 1 ArH (d) 
........ 
w 
TABLE XI (Continued) 
Structure Cpd. Plate Solvent 
98 
,..._ 
(e) 95 DCC13 0 -H Ci) 
0 
(d)~ 
(d) (d) 
OCH3 
(k) 
o (p.p.m.)a Integr. 
7.67 (s) 1 
3.52 (s) 2 
3.85 (s) 3 
7.10-7.40 (m) 3 
7.63 (s) 1 
8.74 (bs) 1 
Assignments 
C=CH (e) 
CH2 (b) 
OCH3 (k) 
ArH (d) 
C=C!! (e) 
OH (i) 
-...J 
~ 
75 
1 142 the formation of the corresponding hydroxymethylene compounds. ' 93, 
94, 95, or 96. Though the existence of tautomeric forms (keto-enol) 238 
,..._ .- ,..,./ 
93 
,.._ 
0 
0 
H 
0 
H 
94 
---
96 
0 
H 
in this type of compound was well recognized, the keto-hydroxymethylene 
form predominates in all cases of our study. This predominate existence 
of the enol form was inferred by the absence of aldehydic proton signal 
in the NMR spectrum and the presence of a definite hydroxyl group 
absorption in the IR spectrum (Plates XVIIIb and XXVb). This is sur-
238 prising in view of published work on simple systems (Table XI). For 
example, our data contradict the results of Terinski and Kozluk238 who 
reported that the amount of keto-hydroxymethylene form decreased with 
ring size in the order of c5 > c7 > c8 > c6 > c9 . 
Hydroxymethylene ketones of this general type are known to cyclize 
h d . d 1 b . h h d . 1,143,236 to y rain azo es y treatment wit y razine. Accordingly, 
76 
the compounds 93, 96, and 94 were treated with 95% hydrazine to give the 
"" .....-v ,,,,,,,....,, . 
corresponding pyrazoles in very good yields (Schemes 8, 9 and 10). 
. 40 146 168 Since two tautomeric forms wete conceivable, ' ' a careful PMR 
spectral analysis was performed; it gave a pattern consistent with the 
existence of the lH form rather than the 2H form (Table XI) as shown in 
Schemes 8, 9 and 10. 
Substituted hydrazines were treated with the appropriate hydroxy-
methylene compound to give a specific product, the N(l) derivative, 64 
which was also consistent with our earlier results. The syntheses of 
the phenylpyrazole 66 and the p-methoxyphenylpyrazole 67 were achieved 
~ - ,.._, 
by treating ketone 94 with phenylhydrazine and p-methoxyphenylhydrazine 
""'"- -
respectively, in glacial acetic acid medium (Scheme 10). The identities 
of the products were verified by elemental analyses, and spectral 
analyses (Tables X and XI). 
In pyrazole formation the imtermediate is presumably a hydrazone 
derivative which might lead to the formation of N(l) or N(2) substituted 
pyrazoles, perhaps depending upon the difference in the nucleophilic 
character of the two nitrogen atoms in the substituted hydra-
zines.17•18•64 The location of phenyl group at N(l) is further sup-
ported by the upfield shifts of the peri hydrogen, marked H(9) (Table 
XI). 
(87.41)--- (87. 79-7.80)-~ 
66 
,,...._,, 
0 
H 
H2NNH2 97°/o 
4bs. CH30H 
'96 ,,...._ 
Abs. CH30H 
85 
_.. 
s ('\ ll'Ol(' 9 
77 
81 
84 
67 
,,.......,, 
~ N-
N' 
I 
® 
I 
0 
CH3 
" H 
H3COC6H4 NNH2 
<>-----
gl H02C_CH3 
0 
s 
90 
-
HC02C2Hs 1 Benzene 
NaOCH3 
0 
H H 
0 C6H5NNH2 
-----t> 
~ gl H02CCH3 
H2NNH2 7°/o Abs. CH30H 
65 ,.._ 
Scheme 10 
66 
--
-...J 
00 
79 
Synthesis of ~-substituted pyrazoles was actually stimulated by 
. 231 
the observation that certain tetrahydroindazoles such as 99 and 
-
100203 exhibit analgesic and herbicide activities, respectively. 
-
99 IOG 
..._.. ~
The synthesis of isoxazole ·derivatives §§, ~' and!}. was accom-
plished via treatment of the required hydroxymethylene compounds with 
hydroxylamine hydrochloride in glacial acetic acid (Schemes 9, 11, and 
12). 111 If the reaction was performed 
isoxazole 88 was obtained (Scheme 12). 
-
in pyridine, isomeric [l,2-~)-
13 CMR spectral analysis strongly 
supports the structures given for the two isomeric isoxazoles. The 
13cMR data and possible mechanism of formation of the two isomers is 
discussed later in this chapter {page 101 ) • · 
During the investigation of the reaction of certain a-hydroxy-
methylene ketones with hydroxylamine hydrochloride, a remarkable dif-
ference in behavior was noticed. In cyclic systems where n = 1 
(cyclopentanone derivatives, 95 and 98), the hydroxylamine nitrogen 
- ,...._ 
became a bridge between two ketonic rings, while the compounds (93, 94, 
,.._ ·-
and 96) where n = 2 and/or 3 were smoothly transformed into the cor-
_,_. -
responding isoxazoles. This general phenomenon was first observed by 
141 Johnson and Shelberg in simple systems. The resistance to formation 
of intermolecular condensation products in the case of cyclopentanone 
derivatives may be due to strain in the 5-5-6 fused ring system. It was 
-u 
:I: 
:t: 
0 
2 
N 
:I: 
.in 
:I:. 
N (.;) 
UN 
0 
:c 
... 
rt) 
:c 
u 
0 
d 
z 
Q) 
c 
Q) 
N 
~ 
Q) 
m 
80 
H3 CO 
89· ,.._. 
H02C C2 H5 
Na0CH 3 . b 
Benzene H3 CO 93 ,,,.._ 
H2NOH ·HCl 
-----C> 
Pyridine 
H3CO 
H2NOH·HC1 
Na"02C.~H3 
CH3pH 
'H2NOH·HC1 I gl HOAc 
H3CO 87 ,.._ 
Scheme 12 
Na.02C CH3 
\~02CCH3 
,,--
00 
~ 
82 
H2NOH · HCl 
-------(;> 
where n = 2 or 3 
0 ?H .·Qt@ CH-N-~H 0 
!! {CH2)n 
where n = 1 
also noted that 95 and 98 failed to condense with hydrazine to give the 
""-' ,,..._ 
corresponding pyrazole. This anomalous behavior is probably also 
'o 
0 
H 
95 98 
,......._. 
attributed to strain effects. Analogous to the formation of isoxazoles, 
formation of pyrazole ring from the six and seven membered ring compounds 
(93, 94, and 96) was done with greater ease and efficiency (Table X). 
-- ..- ~ 
Formation of the sulfone derivatives ~ ?J., Z3_, and J]. was sue-
cessfully achieved by the reaction at room temperature between the 
corresponding compounds 65, 66, 68 and 90, respectively, and 30% 
--...,.... ~ ............ ~ ~ 
l1ydrogen peroxide in glacial acetic acid (Scheme 13). In the case of 
93 
,,...._ 
0 
0 
H 
94 
-
-
0 
H 
the phenyl derivative 66 upon treatment with excess of 30% hydrogen 
...... 
peroxide gave the sulfone N-oxide 71. 
83 
NMR spectral analysis was indeed very useful in the elucidation of 
the structure of the sulfones. For isoxazole 68, the hydrogen peri to 
-
the sulfide function [H(6)] appeared as a multiplet at o 7.10-7.40 along 
( 8 7.1-7.4) 
L(6) 
(4)-.. -- (84.00) 
68 72 
~ ---
with two other aromatic hydrogens. Proton H(9) appeared as a multiplet 
at 7.60-7.80 ppm. Upon conversion of the sulfide to the corresponding 
sulfone 72, the peri proton [H(6)] was shifted downfield (a 7.80-8.10) 
and appeared as a multiplet along with the H(9) proton. The methylene 
----~t> 
gl H02CCH3 
68 
,.-..._.. 
--~~~<> 
gl H02CCH3 
65 
------<> 
gl H02CCH 3 
66 
-
Scheme 13 
84 
72 
~
70 
-
71 
\ + -N-0 NI 
@ 
85 
proton H(4) experienced 0.43 ppm paramagnetic shift [from 8 4.00 (68) to 
8 4.43 (72)] when the sulfide was oxidized to the sulfone. A similar 
chemical shift pattern was observed in other cases (65-+ 70 and 66-+ 71) • 
....... ............ ,,,,....,., ~ 
It was difficult to identify the proton peri to the c~rbonyl function in 
the sulfone 73 derived from thiochroman-4-one because of a presumably 
-
r(8) 
(87.92-8.17) 
73 ,.._ 
equivalent influence of the sulfone group on the proton in position 8. 
These two protons H(5) and H(8) gave, therefore, superimposed signals in 
the form of a multiplet at 8 7.92-8.17. Actually the proton at C(5) 
previously appeared as a doublet at 8.06 in 90 [before oxidation to 
-
sulfone (73)]. One plausible mechanism.for the formation of sulfones, 
.,...., 
such as 73, is given in Scheme 14. 
-
Condensation between the hydroxymethylene group and an amide func-
tion of urea or thiourea led to the formation of compounds 76, 77, and 
- ,.,..., 
].§_. This is analogous to the formation of isoxazoles (in acetic acid 
medium) (Scheme 15, page 87). Careful NMR and mass spectral analyses 
support the structures; but this does not supply unequivocal evidence 
to eliminate compound 76a. The presence of various tautomeric forms 
-
explained in Scheme 15 were evident from the NMR data (Table XI). 
Thiourea derivatives J.1 and ~ also exhibited similar tautomerism as 
indicated by the NMR analysis (see Table XI). 
C?i 
H·C-C-OH 3 t 
0-0-H 
I 
H 
0 
II 
H C-C-0-0H 3 
.. 
R-S-R f\ 
.. 9J 
H 
r ~ II 
,o-o-C-CH3 
-0 
Step( I) I H C-C-OH 3 I 
0-0H 
H' + 
Step (2) Jt 
Step(3) crH 
H C-C-OH 
+H20 3 Iv 0-0-H 
Step(4) R-S -R 
1+ 
@,H 
?J 
O=C-CH3 
Step (5) l -CH3 .:JOH 
R-S-R 
II 
0 
0 
.. 
R-S-R 
II 
Steps(4)8(5) II 
R-S-R 
II 
0 0 
Scheme 14 
86 
87 
76 
,.._, 
88 
0 0 s 0 II II 
c c 
N/ 'NH N/ 'NH H 2 H 2 
H3CO 
76 78 
.,,......, ....._... 
0 
77 
-... 
Interestingly, a fortuitous discovery was made in attempts to 
char·acterize thiochroman-4-one 90. Oximation of thiochroman-4-one 
-
occurred with hydroxylamine. The oxime 74 (m.p. 98-100°C), on standing 
"'"' 
for one hour in an amber-colored bottle, changed from a white crystal-
line solid to a red waxy solid. The NMR spectrum indicated formation 
of a lactam. This change was again noted two days after a freshly pre-
pared sample of the oxime had been dissolved in DCC13 (for NMR analysis). 
The trace of acidic protons known to be present in commercial HCC13 
(DCC13 contains a minute amount of HCC13) might have catalyzed the 
Beckmann type rearrangement. This proved interesting and suggested 
caution since the conversion of lactam "j2, was as rapid even in a very 
pure, spectroscopic grade solvent that the identity of the oxime was 
difficult to confirm via NMR analysis. A reasonable mechanism is 
proposed in Scheme 16. 
NOH 
00 ~+ -(> 
Scheme 16 
89 
0 
©(j 
75 
-
A Study of the Spectra and Acidity of 
4,5-Dihydro-lg-benz[~]indazol-7-ol 
(82) and 2,3a,4,5-Tetrahydro-7-
,_, 
hydroxy-3a-methyl-3g-benz(~)-
indazol-3-one (80) 
-
90 
6-Methoxytetralone (89) was condensed to give the hydroxymethylene 
,.._ 
ketone 93 which was then treated with hydrazine to yield the methoxy 
pyrazole §.!; and which, on further boiling with 48% hydrobromic acid, 
. 191 produced the desired hydroxy pyrazole compound 82 (Scheme 17). 
,,,_.., 
Hydroxypyrazolone 80 was realized by the condensation of the a-keto 
-
ester 97 with hydrazine followed by treatment with 48% hydrobromic acid 
(Scheme 18). The structures of both methoxy- and hydroxypyrazolones, 
79 and 80, respectively, were confirmed by element.al analysis as well as 
,..; -
PMR spectral data. PMR analysis of the hydroxypyrazolone _§..9 in DMS0-~6 
revealed signals at o 1.18 (CH3 , 3H), 2.52 (NH and OH, 2H), 1.68-2.06 
(CH2 , 2H), 2.84-3.12 (CH2 , 2H) and 6.68-7.52 (ArH, 3H). This is to be 
compared with the spectrum of methoxy pyrazole 79, having signals (in 
-
pyridine-~5 ) at o 1.31 (CH3 , 3H), 1.62 (NH, lH), 1.78-2.12 (CH2 , 2H), 
2.76-3.08 (CH2 , 2H), 3.68 (OCH3 , 3H) and 6.77-7.94 (ArH, 3H). Deuterium 
oxide exchanged the protons in the compound 80 at o 2.52 and thus con-
-
firmed the assignment of acidic protons. 
60 It was recently found that the hydroxypyrazole 82 inhibited 
---
growth of Bacillus subtilis W23 and Escherichia coli. The possibility 
of tautomerism in both compounds Ji9 and 82 exists, a situation docu-,..., 
205 
mented in simpler systems. A UV spectral analysis of pyrazole 82 
,...,, 
in water was performed over the pH range 3.2-9.6. It was anticipated 
0 
~co.00 
~ 
\RGOa02Hs ... 
----t> 
NaOCH3 ti1)'€'0 ~ ' 1_ • 
0 HO 
-- I 
CH 
93· ,,,,.._ 
Schem~ 17 
H2NNH2 
CH30H · 
i-+3CO 
Na02C CH3 
H2NOH·HC1 
CH30H H3 CO 
8l ,,..._ 
87 
-
\.0 
I-' 
0 (CH30)2CO 0 
. NaOCH3 t> 
H3CO CJ:i,3I H3CO 
891 ,_ 9.7 
-
Scheme 18 
0 
II 
COCH3 
----C> 
HaNNH2 H!-CO 
CH30H 7i9' 
-\ 
"" N 
HO 
80 82 
,,,__. ,,,...._ 
that introduction of the carbonyl group in the pyrazole ring (i.e., in 
compound 80) would increase the acidity of the hydrogen on nitrogen. 
"""' 
Such was indicated by the large increase in e at 335 nm at pH 9.6. 
max 
The absorption maxiina, emax, and pH values are given for compounds .§.9.. 
and 82 ('!'ables XII and XIII, respectively). 
,,......,. 
The tnsot significant observation in the spectrum of 82 was the 
--
absorption at 272.5 nm at pH 3.2 which disappeared at pH 9.6 with the 
appearance of a strong absorption at 280 nm and concomitant loss of 
shoulder at 294 nm. It has been noted previously that formation of a 
phenoxide ion can result in a bathochromic shift from 270 to 280 nm in 
t 213,232 wa er. Considering the change at pH 9.6 and pH 3.2, the blue 
shift could result from hydrogen bonding, which is known to lower the 
energy of the n orbital. 213 , 232 One might expect this absorption peak 
(at pH 3.2) to be found at a shorter wave length. However, nitrogen 
93 
atoms present in the compound under investigation are potential chromo-
phores which could be effective in shifting the absorption toward the 
near visible; hence the peak's position may be justified. An addi~ional 
absorption (294 nm) identified (at pH 3.2 and pH 6.0) in the form of a 
213 
"shoulder" may be due to ri-TI* transitions of the nitrogen electrons. 
Likewise, the bands at 205 and 207 nm ar.e probably due to 1T-7T* transi-
232 tions in the benzene system. 
94 
TABLE XII 
ULTRAVIOLET ABSORPTION DATA FOR COMPOUND 80 
. IN AQUEOUS MEDIUM AT lo-5 M ,,_ 
Wavelength 
e: pH (nm) max 
3.7 202 14,664 
2.25 7,332 
300 13,254 
7.5 202 14,946 
226 7,050 
307 12,126 
9.6 206 13 ,254 
273 6,486 
335 18,612 
TABLE XIII 
ULTRAVIOLET ABSORPTION DATA FOR COMPOUND 82 
IN AQUEOUS MEDIUM AT 10-5 M ,.., 
Wavelength 
e: pH (nm) max 
3.20 205 5,803 
272.5 3,839 
294 (shoulder) 2,366 
6.0 205 6,607 
270 4,286 
294 (shoulder) 1,696 
9.6 207 5,803 
280 3,839 
95 
Titrations of aqueous solutions of 82 with standard, aqueous sodium 
-
hydrbxide and standard aqueous hydrochloric acid revealed two inflec-
tions with pK values determined to be at 9.1 and 3.7. Pyrazole has a 
a 
reported pKa of 2.5181 and phenol a value of 9.89. 181 Thus, a first 
approximation would assign the value of 3.7 to the ionization process 
involving the proton on nitrogen in cation 82a (or cation 82b) (Scheme 
--- -
~N ~ ~N ~ 
H +~H / " 'H + H+ + H ... 
19). The pK value of 9.1 value is likely due to the ionization of the 
phenolic proton. The remaining proton on nitrogen can scarcely be 
3 involved since pyrazole itself is reported to have a pKa at about 14. 
Unfortunately, the UV spectrum of a close, structurally-related 
model system for the pyrazole 82 could not be found in the literature. 
-
However, PMR analysis in pyridine-~5 revealed a signal at 8 12.4 (NH or 
OH, 2H) indicating two acidic protons [other protons are at 8 2.78 
(CH2-cH2 , 4H) and 6.78-8.12 (ArH and -C=CH, 4H)]. Thus, together these 
data support the structure but do not give unequivocal evidence to 
eliminate the presence of tautomer 82a or 82b in neutral solution. 
- ---
If dimer formation via H-bonding occurs, as was previously indi-
3 6 
cated from an infrared analysis of pyrazole, ' the difference in 
steric requirements for the dimers would probably not be as great as 
estimated from Courtauld models. Also, PMR studies on a series of 
pyrazoles support the presence of dimers of pyrazole in DCC13 and 
96 
"' J: 
., I 
s e ...... .. I 
.£ .£ 
" " l:i~ f-+ ... = a • 
= § § 
.. .. 
ll ti 
.c .c 
0 0 0 
071 ~ © ®~1 ~ 0 <D 
O'I 
..,;,___ r-1 
---'7 
QJ 
s QJ 
,..c 
(.) 
C/) 
0 0 @~1 i J: ©~1i J: 
,.c \ 
~{ 
97 
92 
and CF3co2H. Intuitively, pyrazole ~ in water might be less stable 
than pyrazole 82a since both double bonds in the srhallest ring of 82b 
- -
are exocyclic to a six ... membered. ring. 
As part of a study of heterosteroids and model systems, the syn-
thesis of pyrazolone. 80 provides a carbonyl group in the appropriate 
- . 
position of the smaller ring (for possible improved biological activity 
since the heterosteroids are related to equilenin) which could promote 
enolization. Although several careful studies have been made of the 
tautomerism in various 149 222 pyrazolones, ' the closest simple model 
systems for 80 are 102 and 103, which were reported to exist in both 
~ ............ _.._. 
0 OH 0 OH 
'-
I N , c::: 
CNH 0 (:t ~a 
' H3C l\.CH3 H3C 'C6 H5 H3C 'C6 H5 H3C CH3 
102 102a 103 103a 
'""'-'" 
- -
-~ 
enol and oxo forms in water by IR, UV and PMR analysis. Acidity 
measurements in water gave pKa value of 8.23 and 8.91 for ~ and ~' 
respectively. 150 An order of stability of tautomers in water was given 
in a later paper as shown below. 149 13cMR. confirmed the existence of 
the enol form 104a rather than oxo form 104, while nonenolizable 105 
-· - --
0 
. A-C1;H""--5 _, R~;j <e 
104 
-
R 
OH 
A-csHs ~~I 
104a 
-
showed only a carbonyl carbon atom in DMSO as expected. 237 A.recent 
98 
report tentatively suggests that compound 106 exists in the enol form in 
--
DMSO (PMR study). 78 In a polar medium, 106 was not expected to be a 
- . 
good candidate on the basis of the stability studies of pyrazolones 
reported earl-:i..er, 149 although a br.oad two-proton signal was observed in 
78 the PMR spectrum for~ at o 10.65 (NH or OH) (pKa = 9.69). 
7 
H3CO 
106 79 79a 
If we consider 80 and 80a in our study (S.cheme 20), IR analysis 
,._ ---
-1 (solid state) showed a strong peak at 1639 cm • [This is a dramatic 
shift compared to the ether precursor ]j, which had vC=O at 1686 cm.] 
The latter supports the oxo form 79 rather than the enol form 79a. 
- -
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There was also a broad band at 2824-3125 cm-l with maxima at 2898, 
-1 3030, and 3125 cm , which support the presence of aliphatic and 
100 
aromatic C-H bonds in 79. 
,.....,. 
149 For comparison, compound 107 is reported 
-1 
to have VC=O at 1715 cm in HCC13 and a doublet in CC14 at vC=O at 
1734 and 1718 cm-l -1 Since !!2 has vC=O at 1639 cm (KBr disc), perhaps 
H-bonding dimers or higher:....order polymeric~type .structures exist in the 
149 150 
solid state as suggested for certain pyrazolones. ' Credence is 
lent to this tentative supposition by the high melting point (328°, 
with decomposition) of 80. Mass spectral analysis gave the correct 
---~/~ (216) for M+,· but dissociation of a dimer could have occurred in or 
near th~ ion source (250°) prior to decomposition. 
Titration (in water) of 
surprisingly between that of 
§.9 (or~) revealed a pKa of 8.7, which is 
106 (9.69) 237 and 102 (8.23) and close to 
--- _....,, 
that of 103 (8.91). 150 Recall that the latter is believed to exist as 
---
106 102 103 
--- - -
equilibrium mixture (page 97) 102 
----
102a and 103 ~ 103a. 150 
A tentative assumption is that the pKa of 8.7 for~ represents an 
average value not only for a tautomeric mixture (H on either of the two 
N atoms) but for the phenolic form also. 
The ultraviolet spectrum (in triply distilled water) of the 
pyrazolone 80 gave absorption maxima of high intensity as shown in 
,,..._. 
Table XIII. Good correlation of these intensities and maxima with data 
101 
for known close model systems is difficult because of the additional 
absorption of the arene. portion of 80. However, the intensities for 
,,,..._ 
~150 and ~150 contrast somewhat with those for ~.149 In aqeuous 
149 
media, a predominance of llOa (rv 80%) was suggested • 
. --
(~-CH3 0 OH 0 Q-CH3 HCOH , {,r H C N-CeHs <:: H C N-CH3 H C NH 
3 3 3 3 
108 109 110 llOa ,,..._ 
- -- ---
In 80, the maxima at;\= 225 nm (pH= 3.7 and at;\= 226 nm (pH= 
-
7.5) have intensities close to that of llOa at ;\ = 238 nm (pH= 5.2) as 
""'"""'-
illustrated and are probably comparable thereto on the reasonable 
assumption the maxima are due to Tr-Tr* transitions. Since position 3a in 
80 does not possess an enolizable proton, exact comparison of these 
...... 
tautomeric systems must be treated cautiously, however. This is 
reinforced by the recent work showing ~ the preferred tautomer rather 
than 104. Nevertheless, in 80 there is no driving force to favor 80a 
-- - -
as there is in 104a ~ 104 where a phenyl ring on nitrogen might pro-
--...... -
vide such driving force to favor 104a. Thus, taken on the whole, the 
,,,..,.._ 
evidence suggests tautomer 80 predominates over 80a in the solid state 
- ,,...._, 
as well as in aqueous solution. 
Structural Determination of TWo Isomeric 
Isoxazoles via 13CMR Analysis 
Two previously known isomeric isoxazoles 87 and 88 were synthesized 
,...., --- . 
from a-hydroxymethylene-6-methoxy-l-tetralone~)and hydroxylamine 
102 
hydrochloride. The possibility exists that these two isomeric isoxazoles 
• 13 
may be distinguished by CMR spectral analysis. Four sets of reaction 
conditions (Scheme 12) could produce one or both isomers. Since dis-
agreement is still found in the literature112 , 183 as to the formation 
and identity of the two isomers (and in view of much NMR data supporting 
two structures), a critical 13cMR analysis seemed a plausible means to 
solve this problem. 
112 According to Guthrie and co-workers, reaction of the hydroxy-
methylene compound ~ with H2NOH•HC1 in acetic acid containing sodium 
acetate afforded the [2,3-~]isoxazole ~· Supposedly, H2NOH·HC1 in 
0 
H 
0 
I llf \ ,,....._. 
~ 0 o~ 'N--= 
H2 113 
--- --
pyridine yielded a mixture of the isomeric isoxazoles from which the 
[3,2-~]isoxazole 113 was isolated by the previously prescribed ,,.._ 
th d 173,175,251 me o • 141 Johnson and Shelberg (and more recently Jacquier 
138 
and co-workers ) found isoxazole formation in acetic acid medium 
H3 CO 
89 ,..._.... 
H02C C2Hs 
NaOCH 3 t> 
Benzene H3 CO 93 ,,,.._ 
H2NOH • HCl 
-----C> 
Pyridine 
H3CO 
H2NOH·HC1 
Na02C CH3 
CH30H 
H2NOH·HC1 I gl HOAc 
87 ,.._ 
Scheme 12 
Na02CCH3 
H02C CH3 
~ 
t-' 
0 
w 
104 
gave the [2,1-~]isomer. If the reaction was carried out in pyridine, 
112 the isomeric. [l,2-5:Jisoxazole resulted. However, no x-ray data are 
available. 
183 In contrast to an analogous example in the literature, (accord-
· M d k 183) "f h . . . f d d' tl ing to eyer an co-wor ers 1 t e ox1mat1on was per orme irec y 
on the hydroxymethylene ketone 114 by the general procedure (using 
~ 
hydroxylamine hydrochloride in acetic acid), isomeric [l,2-£]isoxazole 
115 was the major product, accompanied by the other isomer (34%) • 
...._ 
Again, x-ray data are lacking • 
. H2NOH · HCl . 
-------<> 
gl ,HP2CCH3 
11'5 
-· 
In our investigation (Scheme 12), PMR. analysis of the products 
obtained from methods A, B and C (see Experimental) revealed them to be 
identical. When the reaction was carried out in pyridine (method D), 
isomeric [l,2-£]isoxazole resulted. These findings are in good agree-
ment with reports in the literature19 for somewhat similar systems. For 
example, a difference in chemical shift of 0.05 ppm was observed for the 
vs. 
. h 19 two isomers s own. We found a difference of 0.06 ppm between the 
chemical shifts of the indicated heterocyclic protons of isomers 87 and 
.~ 
88. 
-
H (o 8.11) H (o 8.05) 
H3C 0 H3co 
(o 3.83) (o 3.75) 
87 88 
.r-J ,-..J 
The primary question that arises is whether this small chemical 
shift difference derived from PMR analysis can be accepted with con-
fidence. It may be noted that a larger difference in .chemical shifts 
(0.08 ppm) occurred in the protons of the methoxy groups of the two 
isomeric isoxazoles which is not easily rationalized. Since PMR data 
cannot unequivocally substantiate one structure, a 13cMR analysis was 
· d d f 1 b f h · t · · f 13c consi ere more use u ecause o t e enormous sensi ivity o 
105 
chemical shifts to structural changes. 38 , 77 , 108 Another interesting 
property of 13cMR spectra is that each carbon atom of the skeleton and 
its coupling with any attached group (NMR active) may ordinarily be 
individually examined. 
Since the compounds 87 and 88 differ mainly on the location of 0 
,,,...._. -
and N atoms, the bonded carbons should be affected more, i.e., C(lOa) 
and C(3) should have a different 8 value in 87 compared to 88. It was 
........... -v 
8 
87 
.----
106 
gratifying to find a major change in the chemical shifts with respect to 
these positions. Assignments were made by comparison with model systems 
116, 117, 118, 119, and 120. 
•-""- ~ ............... ·~ ~ 
It has been found that methoxy carbon at C(7) can readily be 
identified along with the aromatic carbon atom C(7) itself, from 
similarly documented model compounds 116, 117 and 120~ Thus o 55.2 (for 
- "'"'\.- ._..._ 
both compounds 87 arid 88) was assigned to the methoxy carbon. Signals 
. ............. ......... 
at o 161.1 and o 161.4 were assigned to C(7) in compounds 37 and 88, 
- """'-
respectively. The signals of o 112.4 and o 114.9 (for 87) were 
attributed to C(6) and C(8), although this assignment is tentative. 
Similarly o 113 and o 114.8 were assigned to C(6) and C(8) of isoxazole 
88 (compare model compound 120). 
......... -..... 
The resonance signals at o 110.8 (for 87) and o 114.2 (for 88) may 
•""-' '"'""' 
be assigned to C(9). This must be considered tentative also. The 
signals at o 139.2 (for 87) and o 140.6 (for 88) can be assigned to 
- ............ 
C(ll) (compare model compound 120). The difference in chemical shifts 
......,._ 
f C(lo) b . 'b d d'ff . . 107,139,219,224 or may e ascri e to i erences in strain. The 
upfield shifts resulting from steric interactions with the c-ring is 
evidenced from the observed shift trends (o 123.5 for 87 and o 126.5 for 
'"'-" 
88). Again the 3 ppm downfield shift for 88 may be due to lesser degree 
'""" _..... 
of strain in comparison to 87, where a larger oxygen atom occupies the 
----
place of a nitrogen atom. Carbons C(5), C(4) and C(3a) can readily be 
identified by reference to 119 and 120. In both cases upfield shifts 
,....___ 
experienced by C(4) may result from steric interactions with a 
TI-electron cloud which was absent in both model compounds 119 and 120. 
""'-"" .......... 
As expected, two resonance signals underwent substantial changes and 
may thus be easily assigned to the carbons C(lOa) and C(3). The carbon 
(8160.1) 0 
H3co-@-~ =N -@-oc~ 
t . . 
(855.3) !.!.§. (IN DCCl3 ) 
CCl (8159.0 l 
lr\\__bH ~OCH ~ ~+3 
U_? (IN DCCt 3) t (8 55.0l 
(8113.5) 
(8 160.8) 
( 8 126.1 ) ( 8 131. 9 ) 
0 
~ (IN DCC13 ) 
(3114.4). 
(8157.5) 
H3CO 
t (855.0) 
~--(826.5) 
(829.5)----
(8 23.6 )--__,.. 
---(8125.5) 
"I• (8129) 
(8139.5) ( 8 29.5) 119 (IN DCCl3) 
~
I-' 
0 
-..J 
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which experienced the most downfield shift is likely C (lOa) of cornf•ound 
~and hence the signal at o 165.8 was assigned to C(lOa) and o 149.2 
to C(3) (for 87). At C (lOa) (for 87) the presence of an electro-
........ -...... 
negative atom on a quaternary carbon gave rise to pronounced para-
magnetic shift. For the compound 88, o 158.5 and o 1S2.5 signals may be 
.,......._ 
i 
assigned to C(lOa) and C(3), respectively. Thus, C(3) of 87 can also be 
-
identified by the characteristic quadrapole broadenfng. C(lOa) and C(3) 
signals for both compounds are of lower intensity owing to longer reac-
tion times and lower nuclear Overhauser enhancements. It is interesting 
to note, as expected, that the methoxy carbon atom, possibly because of 
a larger nuclear Overhauser effect, appeared at higher intensity. 
The nuclear Overhauser effect (NOE) is a by-product of proton 
13 
noise decoupling (so that splitting due to spin coupling between C and 
1H will he c~llapsed) in 13cMR experiments. This process disturbs the 
1 169a 13 Boltzmann distribution of the two energy levels of H. The C 
1 i d d . 1 h lH 1 . f . 1 . 1 . 169a nuc e epen main y on t e nuc ei or spin- attice re axation. 
Since the exact magnitude of the NOE depends on the nature and environ-
1 
ment of a specific carbon atom, the integrated intensities of R-
d 1 d 13c . 1 i . 1 1 1 169a,233a ecoup e resonance signa s can vary n a sing e mo ecu e. 
13 This limits the usefulness of proton-decoupled C spectra for quanti-
tative analysis. Experimentally, NOE means that more radiofrequency 
energy will be absorbed by the 13c nuclei ~s a result of the larger 
1 . . h 1 1 1 169a popu ation in t e ower energy eve • 
In the process of format:i,ort of the isoxazole, an oxime may be 
generated. The oxygen atom of the oxime, being.more nucleophilic, may 
attack the carbonyl carbon; this would lead to isoxazole formation. 
109 
When a a.-hydroxymethylene ketone is condensed with hydroxylamine hydro-
chloride in acetic acid, one might visualize two posslble mechanisms of 
formation of the oximes (Scheme 21). The formation of isomeric 
0 
-----(> n:;-i 
(or) 
Scheme 21 
isoxazoles may actually depend upon the kind of intermediate oxime 
formation. The compound 87 might have formed as a result of the follow-,...._ 
ing intermediate oxime. 
~ 
-=NOH 
' 87 
rJ 
In pyridine, ketoxime formation may be favored by the possible 
coordination between hydroxyl hydrogen and pyridine as illustrated. 
This coordination might prevent attack of hydroxylamine at the 
aldehydic carbon atom (the hydroxymethylene form is in equilibrium with 
the aldehyde form). Therefore, the nucleophilic nitrogen may attack 
the carbonyl group as represented to give an isomeric isoxazole. Thus, 
it is now reasonable to assume that the formation of two isomeri.c 
isoxazoles 87 and 88 occurs via two different mechanistic pathways • 
..-... -
110 
• 
~t.°.H---G 
~-OH 
J r 
OH---G 
Molecular Complexation Studies 
A number of physiologically active azasteroids hAve been found to 
. 232a 119 
alter membrane permeability in certain systems. It was reported 
recently that the uptake of 14c-uracil was specifically inhibited by 
10,11-dihydro-3~-naphth[l,2-~]indazol-7-ol (24). But, surprisingly, 
,..... 
HO 
24 
r'"" 
.. 
neither 5-fluorouracil nor mitomycin C (two known anticancer drugs) was 
potentiated by hydroxyindazole 24. 119 It was equally interesting that 
......, 
another anticancer drug, actiromycin D, showed an enhanced activity119 
111 
usen used in combination with hydroxyindazole J:.f!• Since an understand-
ing of the specific nature and physiochemical properties of molecular 
complexes of certain heterocycles (having strategically positioned 
heteroatoms) with anticancer drugs could be instructive, molecular com-
plexes of certain pyrazoles and isoxazoles with 5-fluorouracil (anti-
cancer drug) and with other acceptor candidates have been sd1died in 
this work. A vast literature indicates that formation of molecular 
complexes can be deduced from the analysis of changes in the absorption 
spectra of mixtures and from the NMR chemical shift difference in com-
53a parison with the spectra of individual compounds. 
Our study with a model system included PMR chemical shifts measure-
ments of l,4-dihydro[l]benzothiopyrano[4,3-c]pyrazole (65) (TP) 
- ,,,..._ 
l 
and. 
1,3,5-trinitrobenzene (121) (TNB) and their complexes; the results are 
,.......... 
summarized in Table XIV. As can be observed, the diamagnetic shift 
experienced by the ring methylene protons of the pyrazole group in the 
molecular complex was 0.043 ppm. The aromatic protons (3!:!) of trinitro-
benzene also showed an upfield shift, 0.078 ppm. It is apparent from 
Table XIV that the ring C!:! proton has shifted 0.05 ppm upfield. Since 
the protons on N are somewhat acidic in 65, an intermolecular associa-
...... 
tion could occur between 65 and another identical molecule or with 121. 
~ 
--
The anomalous diamagnetic shift of aromatic H proton, in compar-
a 
ison to Hb protons, suggests the direct interaction of nonbonding 
electrons on one of the oxygen atoms of the nitro group of trinitro-
benzene in the complex. It can reasonably be concluded from the 
observed shifts that the pyrazole system of 65 interacts notably with 
1,3,5-trinitrobenzene. 
TABLE XIV 
CHEMICAL SHIFT CHANGES IN 1:1 COMPLEX OF 1,4-DIHYDRO[l]BENZOTHlOPYRAN0-
[4,3-_sJPYRAZOLE AND 1,3,5-TRINITROBENZENE IN ACETONE d6 
Kinds of Proton with Respect to Chemical Shifts in H;a Difference ~n 
ChemicAl Shifts i ~ n H"&. 
CHzCN 
~ 
F 
HN-N 
©XsY ~ 
@ H , @.1)J ~.--... ~ 
®H~S) 
H 
~,~ g: 
* F 
HN-N 
cOCi + 
uncomplexed uncomplexed complexed 
0.4 
.. 
400.5 399.5 1.0 
i -- -- ---r- ~-- _-- ---r---- -----i 
I Aromatic @ I .. --~--+---· __ 787 _ __t-_____ 1_.o ____ -1 
Aromatic ® 723 
1----------1------------+---------t~·-·-··----- -1----.. ---------·-----1-----------
CH2-CN 392 389.2 2.8 
----- - . . - I - ~ iAromatic @ 725 . . 
Aromatic @ 742.8 i - 741.8 ~-0-·--·· 
-·. _j__ -··--.·- ' ·~---------· I 
I-' 
I-' 
N 
{b) 
(b) 
(b) 65 
·--' 
In Figures 8 and 9 are shown the signals for the ring methylene 
113 
protons of the pyrazole 65 and the 3 aromatic protons of 1,3,5-trinitro-
-
benzene 121, respectively, in both the complexed and the uncomplexed 
........... 
systems. 
The formation of a molecular complex is further substantiated by 
ultraviolet absorption bands recorded in Table XV. 
The most significant feature in the spectrum of the molecular com-
plex is the disappearance of the absorption peak at 245 nm and con-
comitant broadening of the absorption band at 230 nm with simultaneous 
decrease in Emax' A reasonable structure consistent with the observed 
shift trends is given in Figure 10. 
Figure 10. Schematic Representation 
of TP-TNB Complex 
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TABLE XV 
ULTRAVIOLET ABSORPTION DATA FOR 1,4-DIHYDRO[l]-
BENZOTHIOPYRAN0[4,3-_sJPYRAZOLE, 1,3,5-
TRINITROBENZENE AND THEIR COMPLEX 
IN 95% ETHANOL 
Compounds Complex U.V. Absorption 
Wavelength in nM 
HN-N 312 ©rY 245 I 
-5 i (9.636 x 10 m/l) I 
I 
o2N~N02 
I 
230 I 
' 
I 
I l I N02 
1 I -5 I I (9. 636 x 10 m/l)~ . 
I 
I I I 
I 
I 
HN-N 312 
@Y 0 N19J·N02 + 2 0. 
s 230 
"°2 I (broadens) 
-5 9.63 x 10 m/l each 
diluted to 150 ml ; 
(1:1 complex) I 
116 
' 
6max 
'i 
2700 
18580 
29680 
1400 
21810 
117 
30 
20 
10 
0 2 3 4 5 
I 
c"AJ J./m. 
Figure 11. 1 -1 1 A Plot of -t:,.- ppm vs [A] 9.,/m for Methylene Protons 
obs 
of the Pyrazole 65 in the Complex 
,p-P 
118 
21 23 24 136 An association constant, ' ' ' K, was calculated for the 
complex for which the concentration of the donor (pyrazole 65) was kept 
"""" 
constant while the concentration of the acceptor (trinitrobenzene) was 
varied. Methylene protons (S-GH2) were monitored via PMR analysis. The 
singlet absorption: signal and clear pattern of shift trend of the 
acceptor molecule proved instructive. ·The results were tabulated in 
Table XVI. 
The equation21 , 23 , 23 , 117 , 136 used was: 
6 = [A]K 6 
obs 1 + [A]K o 
where 6obs = oDobs - oD0 and 60 = oDAD - oD0 • oDobs = observed shift of 
the donor protons in the complexing medium; oD is the shift of donor 
0 
protons in the uncomplexed state; and oDAD is the shift of donor protons 
in the pure complex. 
The ·reciprocal of the equation may be written as: 
i 1 1 1 
--=---+-· 6 b . K6 [A] 6 0 s 0 0 
K can be calculated from the Y intercept and slope. 
K = y intercept = 1/ 60 j l/K6o 
·slope 
-1 Experimental values of 1/6 b ppm and l/[A] R.,/m were subjected 
0 s 
to linear regression of 1/6 b ppm-1 on l/[A] i/m and the following 
0 s 
values for the slope a.nd Y intercept were obtained. 
Ratio of 
Donor to 6. 
Acceptor 
-
D:A 
1:1 
1:2 
1:3 
1:4 
obs 
TABLE XVI 
CHEMICAL SHIFT OF METHYLENE PROTONS ACCORDING TO 
VARIED CONCENTRATIONS OF THE ACCEPTOR 
1 -1 
in Hz --ppm /}. 
obs 
4.3 23.3 
5.5 18.2 
9.0 11.1 
12.0 8.3 
[A} 
in m/R, 
0.241 
0.482 
o. 723 
0.964 
1 
[A] 
in i/m:-
4.1 
2.1 
1.4 
1.0 
..... 
..... 
\0 
Slope = 4.68453 
Intercept = 5.15325 
K = Y intercept = 
slope 
K = 1.10 'l/m 
5.15325 
4.68453 
The K value was in fair agreement with the reported K values for 
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similar systems such as the !'.!,!'.!-dimethylaniline-1,4-dinitrobenzene 
114. 115 116 117 
complex ' ' ' (K = 0.05 'l/m) and the pentamethylbenzene-1,3,5-
. . ·. 114 115 116 117 trinitrobenzene complex ' ' ' (K = 1.93 'l/m). 
In our investigation of the molecular complexing formation of 
another model system between l,4-dihydro[l]benzothiopyrano[4,3-£]-
pyrazole (65) and 4...;.fluorophenylacetonitrile (122) (4FPAN), a moderate 
,..._ ~ 
diamagnetic shift in the PMR spectrum was experienced only by c~2 
protons of 4-fluorophenylacetonitrile as shown in Figure 12. A summary 
of chemical shift differences was given in Table XVII. 
As indicated, the shift differences were not as significant as 
those of the TP-TNB system. The proton signal for C~ of the pyrazole 
was almost unchanged. However, the aromatic ring proton Ha experienced 
a slight paramagnetic effect (1 Hz). 
Evidence for the existence of a complex in this case was obtained 
by UV analysis, in which the complete disappearance of an R band at 
312 h . h . b bl d * . . 232 '239 d i h nm w ic is pro a y ue to a n -+ '1T transition an s s own 
in Table XVIII. The nonbonding electrons present in the uncomplexed 
state could be involved in the formation of the complex, perhaps via a 
charge transfer mechanism. Based on the results obtained, a reasonable 
structure is given in Figure 13. 
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Figure 12. PMR Spectra Shewing Chemical Shifts 0f Methylene Pret0ns of the Nitrile 122 
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TABLE XVII 
CHEMICAL SHIFT CHANGES IN 1:1 COMPLEX OF l,4-DIHYDRO[l]BENZOTHIOPYRAN0[4,3-.£.]-
PYRAZOLE AND 4-FLUOROPHENYLACETONITRILE IN ACETONE-g6 
Kinds of Proton with Respect to Chemical Shifts in H~ Difference in 
Chemical Shifts 
in H~ 
·-
0 @ HN-N H HN-N H ®~ N-N o2N«o2 H "" o2N~No2 @Y @Yo,•~ @HQ S + o· z (S)H .H@ s 
NO c H N02 N02 2 @ 
uncomplexed uncomplexed complexed 
CH 752 747 5.c 
'S,...CH2 400.5 396.2 4.3 
Aromatic @ 786 778.4 8.4 
Aromatic @ 723 718 5·C 
Aromatic @ 
i 
932.8 925 7.8 
I I 
f-' 
N 
N 
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TABLE XVIII 
ULTRAVIOLET ABSORPTION DATA FOR 1,4-DIHYDRO[l]BENZOTHIOPYRAN0[4,3-.£.]-
PYRA.ZOLE, 4-FLUOROPHENYLAGETGNITRILE 
AND THEIR COMPLEX IN 
95% ETHANOL 
Compounds Complex U. V. ·Absorption 
Wavelength in nM 8max 
©X"9 312 2700 ~ 245 18580 s 
-5 (9.636 x 10 m/l) 
~2~ ' 275 830 
270 882 
F 
-4 (1.9272 x 10 m/l) I 
' 
HN-N 
ocr CH2CN :no 197t + c$J 245 5466 
F 
1:2 Complex 
-4 (2.8908 x 10 m/l) 
I 
I 
I 
I 
I 
I 
Figure 13. Schematic Representation 
of TP-4FPAN Complex 
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Complexation studies involving pyrazole 65 and 5-fluorouracil (42) 
........ ...._ 
could not be successfully carried out because of the low solubility of 
~ in H20 or DMS0-~6 • But UV studies were performed at concentrations 
of 4.6 x 10-5 mole liter per solution of individual compound. The 
significant observation in the spectra was the hyperchromic effect of 
E-bands (200 nm - 220 nm), when the mixture was blanked with the 
pyrazole 65. This may be ascribed to change in electronic transitions 
,,..._ 
in the benzenoid system. 232 Besides this observation, a slight red 
hif f E b d i d i i f * . . 232 s t o - an s was not ce , rem n scent o a ~-~ transition. 
Although an appreciable interaction between the 5-fluorouracil and the 
benzene part of the pyrazole 65 molecule was suspected, the arrangement 
-
of the donor and acceptor in the complex cannot be discerned at the 
moment. 
H 
N F~~ / + complex ;;r 
0 
65 42 ,. 
............ ~ 
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the formation of a molecular complex between 4!![l]benzothiopyrano-
[3,4-d]iSoxazole · (68) and 5~fluorouracil (42) was examined via PMR 
- ,._ -
spectral analysis at a 1:1 molar ratio of solutes (3.J7 x 10-4 mole in 
0 5 . 1 f DMSO d ) I . i d h · d ' · · C-l2 • mo e o .. -_6 • twas conce ve tat rapi tautomerization 
normally e:xhibited by 5-flu()rouracilmight be prevented by interaction 
with isoxazole ·· 68. 
-
Two broad singiets (o 10. 7 and o 11.5) appeared in 
the NMR spectrum when the isoxazole and 5-fluorouracil were mixed 
(Figure 14). These two peaks were absent in the individual species and 
might arise.from possible hydrogen-bond formation as shown in Scheme 23. 
These data must be treated as tentative in view of the known dependence 
for field position of acidic protons on the degree of acidity. 
It was also found in UV spectral analysis that the B-bands under-
went a slight bathochromic shift, which might presumably have resulted 
from a reduction in the energy level of the excited state accompanying 
dipole-dipole interaction and hydrogen bonding. 232 This supports the 
proposed development of H-bonding, and, as shown in Scheme 23, a pre-
ferred organization of both the donor and acceptor in solution is 
quite reasonable. 
Complexation studies between 4,5-dihydro-6,7,8-trimethoxy-lH-benz-
[8]indazole (~2) and 5-fluorouracil (~) were also undertaken (3.17 x 
lo-4 mole in 0.5 ml of DMS0-~6 ) via PMR spectral analysis. To improve 
solubility, 0.5 ml more of DMS0-~6 was added to the mixture (for a 
total volume of 1 ml). The PMR spectral analysis revealed two 
interesting phenomena. A doublet at o 7. 72 (= C-!!) of 5-fluorouracil 
was transformed into a broad signal which appeared at: o 7.66-7.88 in the 
1:1 mixture. When the concentration of the acceptor (3.17 x lo-4 mole) 
was doubled, the broad signal sharpened. The singlet aromatic signal 
•:·--~----~---~~---~ 
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Figure 14. PMR Signal Observed for Acidic Protons in Isoxazole 68~5-Fluorouracil Complex 
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exhibited a diamagnetic shift of 0.023 ppm for the 1:1 mixture and 
0.033 ppm upfield for the 1:2 mixture. These values were obtained 
via analysis of r.esults in scale-expanded regions from o 7-8. 
As a crude approximation, the shift differences substituted into 
the previously cited equation .gave a K value of 2.43 9.,/m. Though the 
[A]K 
3.17 x 10-lK 
0. 01 = -------------- 0. 02 3 
1 + 3.17 x 10-lK 
K = 2.43 9../m· 
K value seems reasonable, we cannot accept it with great confidence 
because of an insufficiency of 132, for which 3-4 more values were 
---
128 
needed for 6 b and 6 • However, there is no doubt that the donor and 
0 s 0 
acceptor interact with each other. Since signals due to the aromatic 
proton and FC=C~ proton were perturbed in the mixture, a ~-cr type 
complex is suspected. With the data available the spatial arrangement 
G 
G 
G=OCH3 
G 
+ 
132 
-.. 
H 
Fo~ ~ complex "' 
0 
42 
~ 
of both the donor and acceptor. atoms cannot be described with absolute 
accuracy. 
Although 3,4-dihydroxybenzoic acid (~) was not a good candidate 
for molecular complexation studies (because it posses~es both donor as 
129 
well as acceptor characteristics) it was selected for complexation 
studies with pyrazole 65 in view of the recent report by Durham and ,,...., 
86a Keudell. They observed that the inhibition of synthesis of amidase 
by actinomycin D, a clinical anticancer agent, could be prevented or 
alleviat.ed by 3,4-dihydroxybenzoic acid and suggested that the two com-
pounds formed a complex that (in this case) inactivated the antibiotic. 
Equimolar quantities of "free" molecules (2.409 x 10-4 mole each in 
1 ml of acetone-~6) were employed. Line broadening.was observed for the 
hydroxyl protons; the lo.w. spin-spin relaxation (smail T2 values) may be 
due to self-interaction of 3,4-dihydroxybenzoic acid in solution. Other 
·b·1· · 53a f l.i· b d i . i · h · possi l. ities or ne roa en ng are magnet c in omogeneity or an 
increase in bulk viscosity as well as self association and/or inter-
molecular complex formation. Since our investigation was carried out 
in dilute aqueous solution, the viscosity variable is'unlikely. 
When pyrazole ~was added, larger T2 values were noted; this may 
be due to suppression of self-interaction of 3,4-dihydroxybenzoic acid 
by the pyrazole moiety. Although it is not illogical to conclude that 
formation of an intermqlecular complex has occurred as shown, the 
53a dependence of 5 values of ~cid protons on concentration precludes 
elimination of alternative structures and explanations. 
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Spin-spin relaxation time (T2 values) is an important technique to 
study the motion of a part of a molecule in NMR spectroscopy. 53a ' ~fiien 
nuclei .are sufficiently close to each other, a realignment of atoms can 
occur. In such compounds, nuclei may exchange spin states, and the 
process of mutual reorientation is hence spoken of as spin exchange. 
This relaxation time, T2 , is related to the width of an absorption line 
at half intensity. 53a If the shape of the resonanccl line is given by a 
Lorentzian curve, T2 is given by the reciprocal of the half-width at 
half-height. Thus any decrease of T2 will manifest itself as a broad-
. f h b · l' 53a ening o t e a sorption 1ne. 
The temperature dependence of spin~spin relaxation time was 
examined for thiochroman pyrazole-3,4-dihydroxybenzoic acid and the 
data are tabulated in Table XIX. As the temperature increased, the 
relaxation time began to increase; dissociation of the complex was 
53a 
suspected. 
Other data supporting the presence of a complex were found via UV 
spectral analysis (4.6 x lo-5 molar solution in et~anol was used). When 
blanked with 3,4-dihydroxybenzoic acid, the spectrum exhibited a new 
absorption peak at 225 nm (e225 = 7609) with a concomitant bathochromic 
shift of the signal at 245 nm to 250 nm. 
Biological Activity 
In cooperation with a group in the Microbiology Department, headed 
by Professor N. N. Durham, it was possible to evaluate the activity of 
compounds on the growth of'microorganisms and KB cells. The primary 
screening was performed to study growth alteration of Bacillus subtilis 
by 91 µg/ml of test compound. This screening process was carried out 
with Pseudotnonas fluorescens and KB cells before screening in mice. 
TABLE XIX 
TEMPERATURE DEPENDENCE OF THE SPIN-SPIN RELAXATION TIMES 
OF 3,4-DIHYDROXYBENZOIC ACID-l,4-DIHYDRO[l)-
BENZOTHIOPYRAN0[4,3-~]PYRAZOLE MIXTURE 
Temperature in oc T2 in Seconds 
0 1.8181 
10 2.1052 
20 2.6667 
30 2. 8571 
40 3.3333 
It is interesting to note that thiochromanopyr~zole ~ has been 
found to inhibit growth in !· subtilis even at a concentration of 
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75 µg/ml. This also exhibited 72% plating efficiency on 12.5 µg/ml and 
a substantial effect was observed at 50 µg/ml (0% plating efficiency, 
100% inhibition). In contrast, the corresponding sulfone 70 showed no 
--
growth inhibition of !· subtilis or Ps. fluorescens. But, the respir-
ation test (with B. subtilis) with 70 showed an inhibition as was the 
- -
case with pyrazole.P2,. Surprisingly, the sulfone derived from 
thiochroman-4-one (!2} produced a 4-hr lag in growth (.!!,. subtilis) along 
with positive results for respiration screen (B .• subtilis, Ps. 
132 
fluorescens, SA-180, L-1210). Isoxazole 68 inhibited growth of B. 
,,,..._. . -
subtilis (overnight) and KB cells (at 50 µg/ml, 100% inhibition of 
cell growth resulted); but Ps. fluorescens was unaffected. The cor-
responding sulfone 72 showed ho apparent biological activity. Bio-
. ......., 
logical testing using higher concentrations of these test compounds has 
yet to be done. Since it has been established that both qualitative 
and quantitative responses of man and other species to cancer drugs 
differ considerably, inhibition of KB cell growth alone may not be con-
sidered as a criterion for possible drug activity in humans. 
Suggestions for Future Work 
41 It has been reported that the most widely used agent for the 
treatment of babesiasis at present is quinuronium methosulfate (135). 
0 H II H N-C-N~ 
+, ~Yd 
CH3 . CH3 
':1..35 
r--
,,,....._. 
Preparation of 136, 137, 138, and 139 seems worthy owing to their 
,,..,.._ - -- -""'--
structural similarity to the compound 135. Starting materials are 
-
available (Aldrich Chemical Company, Inc.) and a reasonable procedure 
for the synthesis of 136, 137, 138, and 139 is available. 
-- --
,_ ..._ 
0 y 0 
II 
~ NC NH 
H R R 
133 
136 x = CH2; y = O· R = OCH3 
--
' 
137 x = CH2; y = S· R = OCH3 
' 
-
138 x = S; y = O; R = H 
-
139 x = S; y = O· R = H 
.. ' ,....,,., 
The following synthetic scheme is proposed. 
0 
HO 
0 
R@:) (1) Hco2c2H5 NaOCH3 C> R Benzene 
(2) W, work up y .. H N-C-NH 2 2 
gl. HOAc 
work up 
0 y o· 
II 
N-C-N 
H H 
R R 
The existence of various possible tautomeric forms might create -great 
difficulties for unequivocal determination of these structures. Aqueous 
solubility can be improved by converting 138 and 139 to their salts. 
~ /'-" 
141 Johnson and Shelberg have prepared the bis indanone derivative 
140 (although the proposed structure is questionable since very little 
......... 
I 
N-CH 
140. 
,-.,, 
134 
0 
evidence was furnished in support of it) and explained the formation on 
the basis that strain prevents cyclization to isoxazole derivatives. 
By applying the same argument (but different reagents), the following 
hydrazo 141 and hydrazono 142 compounds may be made on the following 
,...._ ---
0 
cH1oH (abo) 
unaer N2 
tentative (but plausible) scheme. 
~~H~ ~~N~~ 
. 141 
©:>R~(=<:@J 
142 ,..._,,, 
The structure determination may be 
achieved by condensation of the hydroxymethylene compound with various 
substituted hydrazines. 1,2 Substituted hydrazines cannot undergo the 
reaction yielding compounds of type 142. Pyrazole formation can also 
--
occur (contrary to Johnson and Shelberg 141). 
Preparation of a propionic acid derivative 143 of thiochroman-4-
..--
one may be accomplished by the following route. Once the preparation 
of 143 is successfully completed, equilinin-type ~odel compounds may 
""-" 
readily be prepared by procedures perfected by Dr. Berlin's research 
group, Department of Chemistry, Oklahoma State University, Stillwater, 
Oklahoma. 
135 
0 
~ 
~s) 
(1) NaOCH3 CzHs 
...... ~-~~~-~(> 
(2) c 2H50CH = C(CN) 2 
or 
. c2H50CH = C(co2c2H5) 2 
(3) H+ 0 6., Work up 3 
143 
~ 
A long-known drug, sulfonal, has the following structure. Com-
pounds having similar functionalities can be prepared from readily 
available materials.as shown on page 136. 
A common mechanism of action in one type of drugs used in cancer 
chemotherapy (alkylating agent) appears to be the one given below. 
G CH -CH - X 
R-N(J 2 
' CH -CH - X 2 2 
/CH~CH2 
----+) R-N'/ 
\ 
CH2-cH2- X 
x 
So similar functionaliities may be worth introducing into some of the 
systems such as those shown on page 137. Though the procedure seems 
HSCH2cH20H 
0 
~ HSC2H5 ~s) ~ 
HSCH2CH2SH 1---- --- ---- - ------ -·1 -
other 
product 
another 
product 
~ 
then oxidation 
etc. 
SC2H5 
oxidation, 
(probably with H2o2) 
~ 
SC2H5 5<:215 
and other products 
...... 
c..> 
"' 
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speculative, it is quite p.iausible (alkylation at N!! may be expected 
too). 
. N(CH2-cH2~1) i:> 
It is even worth trying to make the following compounds, since 
starting materials are readily available. 
0 
N(CH2-cH2-Cl) 3 
. t> 
0 
tH2cH2-N~H2cH2 cl)2 
0 
@O N(CH2-cH2-c1) 3 ------it> 
138 
By methods analogous to the formation of isoxazoles, the following 
compounds may be prepared. The procedure is tentative, but quite 
reasonable. 
gl. HOAC 
-yn-2-.:N""'s'"li,.._ _ __,C> 
Coupling of two steroidal moieties may be performed by the selec-
tion of proper conditions and use of iodine as oxidizing agent (similar 
207a 224a 243a . 
reaction agent is known) · ' ' to yield the following compound 
144. 
,..___, 
Hf O 
0 0 
144 ,.._, 
The compounds of the types following may also be speculative, but 
can be obtained by methods developed in our laboratory. 
145 
....-
146 
--
s 
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It is my sincere belief that with better understanding of bio-
chemical interactions~ systematic approach to drug design would become 
more.predictive. Complexation studies·with compounds.having Strate-
gically positioned heterciatoms might contribute significantly to this 
prqblem. ln addition to this, complexation studies between (a) vitamins 
(vitamin C) and anticancer drugs (e.g., adriamycin, (b) two anticancer 
drugs, (c) anticancer drugs and cancer-causing agents (c.arcinogenic 
compounds) are worthy to be considered. My immediate selection for 
complexation studies would be adriamycin and digitalis (refer to 
252 Chapter I). Adriamycin causes heart disease and it is possible 
that a combination of this drug and digitalis might not possess this 
undesirable side effect. 
CHAPTER III 
EXPERIMENTALa-h 
All reactions described herein were performed many times on 
various scales with slight modifications in procedures. In general, the 
best results are given and the following are representative descriptions 
aMelting points were determined with a Thomas-Hoover capillary 
melting point apparatus and are uncorrected in degrees Centigrade. 
bProton magnetic resonance spectra were obtained on a Varian XL-
100 (15) high resolution NMR spectrometer (with a time-averaging computer 
accessory, C-1024) operating at 100.1 MHz with tetramethylsilane (TMS) 
used as an internal reference. The spectra were consistently recorded 
using a 10 ppm sweep width with the signal from TMS as reference. Any 
signals which fell beyond 10 ppm were shown with a separate plot of 
those signals using an offset base-line near the left side of the 
spectrum. For some compounds, expanded plots were included for key 
regions for the sake of enhanced resolution. Each spectrum was directly 
photographed from an original black-ink recording on blue-grid chart 
with omission of the grid lines. 
cCarbon-13 NMR spectra were obtained using a 200 ppm sweep width 
with the signal from TMS appearing at zero using external F-19 lock. 
dUV spectra were obtained on a Cary 14 Spectrophotometer. 
eIR spectra were taken on a Beckman-SA spectrophotometer with sam-
ples in potassium bromide pellets or films on sodium chloride plates. 
Each spectrum was directly photographed from an origin~! red-ink record-
ing on golden-grid chart paper. 
fLow resolution mass spectra were obtained on a CEC 21-lOOB double 
focusing mass spectrometer unit. For some compounds peak matchings were 
carried out using PFK as reference. 
gElemental analyses were performed by Galbraith Laboratories, 
Knoxville, Tennessee. 
hCommercially available reagents were used without further purifi-
cation unless otherwise specified. 
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of the procedure developed. 
Preparation of 2-Hydroxyrnethylenethiochrornan-4-one (94). Corn-
rnercial sodium rnethoxide [2.7 g. (0.05 mole); Fisher Scientific Company, 
"purified" grade] was suspended in 20 ml. of anhydrous reagent-grade 
benzene in a previously dried 200-rnl., 3-necked, r. b. flask fitted with 
nitrogen inlet. Ethyl formate [3.7 g., 0.05 mole; Matheson Coleman and 
Bell] was then added and the mixture was cooled to about 10°C with an 
ice bath and magnetic stirring. 
Thiochrornan-4-one [Aldrich Chemical Company, 4.1 g. (0.025 mole)] 
in 25 ml. of anhydrous benzene was added dropwise to the reaction mix-
ture, the temperature being kept at 10-15° with an ice bath. After the 
addition was completed, the reaction mixture was allowed to warm at room 
temperature, at which it turned to a semi-solid, reddish mass, and 
stirring was stopped. The mixture was left overnight. 
Hydrolysis of the reaction mixture was effected with 100 ml. of ice-
cold distilled water, and the resulting organic layer was washed succes-
sively with distilled water and with aqueous 10% NaOH. The combined 
aqueous extracts were washed (ether, 3 x 25 ml.) and then acidified with 
dil HCl (pH= 6). A brown-colored liquied formed; this was extracted 
with ether (5 x 25 ml.), washed (satd. NaCl, 25 ml.), and then dried 
(MgS04). Evaporation of the ether gave 4.2 g. (87.5%) of 94 as a crude, 
-
waxy red oil, which was used in the following procedures without further 
purification. Characterization of the structure was done by IR and :NMR 
(Plates XIXb and lb) analysis. The molecular weight found by mass 
spectral analysis was 192. 
Preparation of 4H-[l]Benzothiopyrano[3,4-d]isoxazole (68). 2-
-
Hydroxymethylenethioch~ornan-4-one (94) (1.8 g., 0.0094 mole) was 
...._ 
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dissolved in 30 ·ml. of glacial acetic acid in .a ldO-ml. 2-necked, r. b. 
flask equipped with an addition funnel and water condenser. Hydroxyl-
amine hydrochloride (1 g., 0.0145 mole) in 5 ml. of distilled water was 
then added dropwise at room temperature with constant stirring (magnetic 
stirrer). The reaction mixture was heated to a boil for 0.5 hr. and 
then cooled to room temperature. After stirring overnight, the mixture 
was triturated with cold water (75 ml.). A crystalline solid separated 
and was filtered out by suction, washed several times with distilled 
water, and air dried. It lV"as then recrystallized (C2H50H) to yield 
1.5 g. (84.3%) of 68,m.p. 71-73°. The molecular weight determined by 
-
mass spectral analysis was 189. 
Anal. Calcd. for c10H7NOS: N, 7.41; S, 16.93. 
Found : N, 7. 18; S, 16. 98 
IR and NMR spectra (Plates XXa and Ila) support the proposed 
structure for 68. 
~ 
Preparation of l,4-Dihydro[l]benzothiopyrano[4,3-c]pyrazole (65) • 
......... 
2-Hydroxymethylenethiochroman-4-one (94) (2.5 g., 0.0130 mole) was 
-
dissolved in 40 ml. of anhydrous methanol in a dry 100-ml. , 3-necked 
r.b. flask fitted with an addition funnel and N2 inlet. Hydrazine 
(3 ml., 97%) in.10 ml. of anhydrous methanol was added dropwise. An 
exothermic reaction ensued with darkening of the already reddish-brown 
methanol solution. The. mixture was then heated to a boil for 15 
minutes and stirred at room temperature for 4 hr. (magnetic stirrer). 
Distilled water (75 ml.) was added to the reaction mixture which was 
heated to boiling with stirring (0.5 hr.). The reaction mixture was 
then cooled in ice cold water. The yellow crystals formed were 
143 
filtered out uncl.er suc.tion arid washed several times with distilled 
water. The air-dried yellow powder weighed 2.3 g. (93.8%) (two crops); 
m.p. 168.5-170°. IR and NMR spectra (Plates XXIa and XVII) were in 
agreement with the assigned structure for 65. 
. ....... 
Anal. Calcd• for c10H8N2S: N, 14.89; S, 17.02. 
Found: N, 14.95; S, 17.08. 
Molecular weight by mass spectral analysis was 188. 
Preparation.of l,4-Dihydro-l-phenyl[l]benzothiopyrano[4,3-c]-
pyrazole (66). The hydroxymethylene compound 94 (1.8 ~., 0.0094 mole) 
""' . . 
--
was dissolved in 30 ml. of glacial acetic acid in a 100-ml., r.b. flask 
fitted with a water condenser. Solid phenylhydrazine (1.2 g., 0.011 
mole) was then added to the solution at room temperature, and it was 
stirred. with a magnetic stirrer •. The reaction mixture was heated to a 
· boil for 10 minutes and then cooled to room temperature. After stirring 
6 hrs. mor~, the mixture was diluted with water (50 ml.), heated to a 
boil, and then allowed to cool at room temperature. The crystalline 
solid that separated was filtered off by suction and washed several 
times with distilled water. The air-dried product was then recrystal-
lized. (dil CH3co2H) to yield 2.2 g. (88.7%, m.p. 169-171°) of pyrazole 
66. The molecular weight by mass spectral analysis was 264. 
Anal. Calcd. for c16H12N2S: N, 10.61. 
Found: N, 10.55. 
NMR spectrum (Plate IIIa) confirms the proposed structure for 66. 
---
Preparation of l,4-Dihydro-1-(p-methoxyphenyl)-[l]benzothiopyrano-
[4,3-c]pyrazole (67). Hydroxymethylene compound~ (1.8 g., 0.0094 
. -
mole) was dissolved in 55 ml. of glacial acetic acid in a 200-ml., r. b. 
flask fitted with a water condenser. p-Methoxyphenylhydrazine (L 8 g., 
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0.013 mole) was then added to the solution with constant stitring 
(magnet:ic stirrer). The reaction mixture was heterogeneous at room 
temperature, but upon boiling for 10 minutes, it became homogeneous. 
After stirring 6 hrs. at room temperature, the mixture was diluted with 
distilled water (50 ml.) and heated to a·boil. It was cooled to room 
temperature. A tarry substance formed a:nd was d.is.solved in acetone 
(25 ml.) and kept for one week. A reddish-yellow trystal mass formed; 
this was filtered out under suction and washed several times with dis~ 
tilled water. The air-dried, yellow pyrazole 67 weighed 0.8 g. (28.98%, 
-
m.p. 145-146°). The molecular weight by mass spectral analysis was 294. 
Anal. Calcd. for c17H14N2os: N, 9.52. 
Found : N, 9 • 4.5 • 
NMR spectrum (Plate IVa) was in agreement with the reported 
structure for 67. 
-
Preparation of 4H-[l]Benzothiopyrano[3,4-d]isoxazole 5,5-dioxide 
(72). 
·-
To a solution of 0.2 g. (0.00105 mole) of isoxazole 68 in 5 ml. 
-
of glacial acetic acid was added 3 ml. of 30% hydrogen peroxide, and 
the reaction mixture was allowed to stand at room temperature (30 hrs.). 
The mixture was diluted with 25 ml. of cold distilled water and cooled 
(ice bath). A white, crystalline solid separated and was filtered off 
under suction and washed (6 x 25 ml.) several times with distilled 
water. The air-dried crude isoxazole 72 was then recrystallized 
-
(CH3co2H) to give 0.22 g. of 72 (94.8%, m.p. 170-172°). The molecular 
·-
weight by mass spectral analysis was 221. 
Anal. Calcd. for c10H7No3s: N, 6.33, S, 14.48. 
Found: N, 6.21, S, 14.38. 
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IR and NMR spectra (Plates XXb and IIb) confirm the reported 
structure for 72. 
-
Preparation of l, 4-Dihydro [ l]benzothiopyrano [ 4, 3-c lpyrazole 5, 5-
dioxide (70). Pyrazole 65 (0. 2 g., 0. 00106 mole) was dissolved in 5 ml. 
-- -... 
of glacial acetic acid. To this solution was added 3 ml. of 30% 
hydrogen peroxide, and the reaction mixture was allowed to stand at room 
temperature (50 hrs.). The mixture was concentrated on a rotary · 
evaporator to a small volume (3 ml.), which was diluted with 25 ml. of 
cold distilled water (as a precaution the concentrating of the reaction 
mixture containing hydrogen peroxide was done slowly to avoid any pos-
sibility of explosion). A crystalline solid separated ancj. was filtered 
off under suction. It was washed several times (6 x 25 ml.) with ice-
cold distilled water and air-dried. The pyrazole tQ. was recrystallized 
(dil CH3co2H) to yield 0.15 g. (64.4%) '].2, m.p. 249-250°. Themolecular 
weight determined by mass spectral analysis was found to be 220. 
Anal. Calcd. for c10H8N2o2s: N, 12. 73. 
Found: N, 12.69. 
The reported structure of 70 is confirmed by IR and NMR spectral 
analysis (Plates XXIb and Va). 
Preparation of l,4-Dihydro-l-phenyl[l]benzothiopyrano[4,3-c]-
pyrazole-2,5,5-trioxide (71). Pyrazole 66 (0.3 g., 0.00114 mole) was 
- -
dissolved in 10 ml. of glacial acetic acid, and to this solution was 
added 7 ml. of 30% hydrogen peroxide. The reaction mixture was kept at 
room temperature (50 hrs.) without stirring. T)le mixture was then 
diluted with 25 ml. of distilled water and cooled in the refrigerator. 
A recrystalline solid separated and was filtered off under suction. 
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It was washed several times (6 x 25 ml.) with distilled water. The 
air-dried pyrazole Z! was recrystallized (dil CHf02H) to give 0.35 g. 
(98.8%) z.!., m.p. 211-212°. The molecular weight by mass spectral data 
was 312. 
Anal. Calcd. for c16H12N2o3s: N, 8.97. 
Found: N, 9.04. 
The proposed structure of 71 was supported by NMR spectral analysis 
(Plate Illa). 
Preparation of Thiochroman-4-one-1,1-dioxide (73). Thiochroman-4-
-.. 
one (90) (2.05 g., 0.014 mole) was dissolved in 25 ml. of glacial acetic 
-
acid and to this solution was added 10 ml. of 30% hydrogen peroxide. 
The mixture was allowed to stand at room temperature (50 hrs.). The 
reaction mixture was then concentrated to a small volume (10 ml.) 
(rotary evaporator) taking extra care to avoid any possibility of 
explosion. The concentrated mixture was diluted with 25 ml. of cold 
distilled water. A crystalline solid formed and was separated by 
filtration under suction. Ketone 73 was then washed several times with 
,,,....., 
distilled water (3 x 25 ml.) and recrystallized (dil CH3co2H) to yield 
1.8 g. (65.7%) 73, m.p. 131-133°. The molecular weight determined by 
-
mass spectral analysis was 196. 
Anal. Calcd. for c9H8o3s: S, 16. 33. 
Found: S, 16.40. 
The proposed structure for 73 was confirmed by NMR spectral 
analysis (Plate Vb). 
Preparation of l-[(4-0xothiochroman-3-yl)methylene]-2-thiourea 
(78). The 2-hydroxymethylene compound 94 (2.7 g., 0.014 mole) was 
·'""'-' ·""""" 
dissolved in 20 ml. of glacial acetic acid. A suspension of thiourea 
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(1. 5 g. , 0. 019 mole) in 20 ml. of glacial acetic acid was added to the 
solution and the resulting heterogeneous mixture was stirred for 14 
hrs. at room temperature using a magnetic stirrer. As the reaction 
progressed, the medium became homogeneous. It was then heated to a 
boil for 10 min. and allowed to stand for 14 hr. at room temperature. 
The reaction mixture was diluted with cold water (75 ml.) for 30 min. 
Crystalline solid separated and was filtered of£ under suction, ~ashed 
several times. with cold water (6 x 20 ml.) and air dried. Recrystal-
lization from dil CH3co2H gave 1.1 g. (31.4%) ~' m.p. 184-186°. The 
molecular weight by mass spectral analysis was 250 (Calcd. for 
c11H10N2os2). Peak matching using PFK was in good agreement with the 
proposed structure 78 . 
...... 
M.S. Calcd. for c11H10N2os2 : ~/~ 250.117349 (~) 
Found: m/e 250.012960 (Mf") 
Calcd. for fragment c10H8NOS: m/e 190.032658 
Found: m/e 190.026492 
Calcd. for fragment c9H6os: m/e 162.013935 
m/e 162.019275 
It was further supported ~y IR and NMR spectral data (Plates XXIIIa 
and VIa). However, elemental nitrogen analysis did not indicate the 
sample t~ be pure. 
Anal. Calcd. for c11H10N2os2 : N, 11.20. 
Found: N, 7.45. 
Preparation of 2-Hydroxymethylene-6-methoxy-l-tetralone (93). 
-
Sodium methoxide (3.72 g., 0.0672 mole) was suspended in 35 ml. of dry 
benzene, ethyl formate (5.1 g., 0.0672 mole) was then added to the 
suspension, and the mixtur~ was cooled to 10° (ice-bath). The system 
• 
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wa.s kept under N2 and stirred (magnetic stirrer). A solution of "6-
methoxy-1-tetralone in 40 ml. of dry benzene was added and the reaction 
mixture turned blue. When the mixture was wa.rined to room temperature, 
it deposited a yellowish-brown precipitate and was allowed to stand 
overnight at room temperature without stirring. 
Hydrolysis of the reaction mixture was effected with 400 ml. of 
ice-cold water, and the resulting organic layer was washed successively 
with distilled water (30 ml.) and with aqueous 5% Na.OH (20 ml.). The 
aqueous portions were combined, washed with ether (3 :x 30 ml.) and then 
acidified with dil HCl and ice (pH= 6). A brown crystalline solid 
formed and was separated by filtration under suction. It was washed 
several times (6 x 25 ml.) with distilled water and air-dried to 
produce 6.7 g. (95.7%) of 93, m.p. 66-68°. This solid was used without 
-
further purification. The structure of the hydroxymethylene compound 
93 was confirmed by NMR analysis (Plate VIIb) • 
........ 
Preparation of [(l,2,3,4-Tetrahydro-6-methoxy-1-oxo-2-naphthyl)-
methylene)urea (~). The 2-hydroxymethylene compound 2] (l.~ g., 
0.0088 mole) was dissolved in 30 ml. of glacial acetic acid, and urea 
(1 g., 0.0166 mole) was added to the solution. The resulting reaction 
mixture was stirred (10 hr.) at room temperature (magnetic stirrer). 
It was then boiled for 10 min., cooled to room temperature, diluted with 
cold water (75 ml.), and let stand for 30 min. Crystals formed and were 
separated by filtration under suction. They were washed several times 
with cold distilled water (6 x 25 ml.) and air-dried. The product was 
recrystallized (dil CH3co2H) to be a 1.8 g. (83.2%; m.p. 235-237°) of 
76. Molecular weight found by mass spectral analysis was 246. 
-
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Anal. Calcd. for c13H14N2o3 : N, 11.38. 
Found: N, 11.15. 
IR and NMR spectral analysis (Plates XXVIIIa and VIIIa) agreed 
with the reported structure for ~· This structure was reconfirmed by 
peak matching using PFK as follows: 
M.S. Calcd. for fragment Cl2Hl2N02: ~/f!_ 202.086798 
Found: ~/~ 202.092692 
Calcd. for fragment Cl2H13N02: m/e 203.103174 
Found: m/e 203. 099577 
Calcd. for fragment Cl2H1202: m/e 188. 083724 
Found: m/e 188.070020 
Preparation of l-[(1,2,3,4-Tetrahydro-6-methoxy-l-oxo-2-naphthyl)-
methylene]-2-thiourea (77). The hydroxymethylene compound 93 (2.5 g., 
- ....... 
0.0123 mole) was dissolved in 40 ml. of glacial acetic acid and thiourea 
(1.5 g., 0.0197 mole) was added to the solution. The resulting reaction 
mixture was stirred overnight at room temperature (magnetic stirrer). 
It was then boiled for 10 min. and tirturated with cold distilled water 
(50 ml.) for 30 min. A crystalline solid separated and was filtered 
out under suction. It was then washed (3 x 25 ml.) several times with 
cold water and air-dried. The product was recrystallized (dil 
CH3co2H) to yield 3.2 g. (99.3%, m.p. 225-227°) of I!..· 
Anal. Calcd. for c13H14N2o2s: N, 10.68; S, 12.21. 
Found: n, 10.52; S, 12.33. 
IR and NMR spectral analysis (Plates XXIIIb and VIIIb) were in 
agreement with the proposed structure for 77. The structure was 
....... 
further supported by peak matching using PFK. 
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M. S. Calcd. for C13H14N2o2s: m/e 262.077593 (~) 
Found: !!!1~ 262.076703 (W) 
Calcd. for fragment Cl2Hl2N02: m/e 202.086798 
Found: m/e 202.084764 
Preparation of Methyl 6-Methoxy-2-methyl-l-oxo-1,2,3,4-tetrahydro-
naphthalene-2-carboxylate (97). A mixture .of 6-methoxytetralone 
-
(6.82 g., 0.0388 ml.), dimethyl carbonate (41.6 ml.) and sodium 
methoxide (2. 42 g., 0. 0448 mole) were boiled under N2 for· 2. 5 hr. A 
yellowish precipitate formed. The mixture was allowed to cool and 
200 ml. of absolute methanol was added to dissolve the precipitate. A 
solution of methyl iodide (9.14 g., 0.0644 mole) in 200 ml. of absolute 
methanol was added, and the mixture was stirred overnight at room 
temperature. The mixture turned greenish in color and was then boiled 
for 10 min. and adjusted with 2N acetic acid to pH 6. Upon cooling, 
compound 97 crystallized as yellow solid. Recrystallization from 
-
methanol gave 54 g. (82%) of 97, m.p. 91-93.5° (recorded m.p. 91-92°) 
-
(IR Plate XXIVa), 
Preparation of 2,3a,4,5-Tetrahydro-3a-methyl-7-methoxy-3H-benz[g]-
indazol-3-one (79). A mixture of keto ester 97 (14.8 g., 0.059 mole) 
- -
and 95% hydrazine (1.92 g., 0.060 mole) was stirred at ambient tempera-
ture under N2 for 4.0 hr. As the reaction mixture thickened, absolute 
methanol (50 ml.) and additional 50% hydrazine (5.0 g.) were added to 
keep the mixture fluid. At the end of the reaction period, distilled 
water (200 ml.) was added and the mixture was stirred (45 min.). The 
product was filtered out and washed (3 x 100 ml. of water) to give 
12.29 g. (90.5%) 79, m.p. 217.5-218.5°. An analytical sample of the 
·-
indazol-3-one purified by sublimation (178°, 0.1 mm., m.p., 218-219°) 
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gave the following analysis. 
Anal. Calcd. for c13H14N2o2 : C, 67.81, H, 6.12; N, lz.17. 
Found: C, 67.69, H, 6.22; N, 12.34. 
IR and NMR analysis suppor.t the proposed structure for 79 (IR Plate 
-
XXIVb). 
Preparation of 2,10,11,lla-Tetrahydro-7-methoky-lla-methyl-lH-
phenanthro[l,2-c]pyrazol-one (83). 3,4-Dihydro-7-methoxy-1(2H)-
""""' 
phen~nthrone (101) (1.75 g., 0.0078 mole) in 45 ml. of anhydrous 
--
dimethyl carbonate was stirred (magnetic stirrer) for 15 min. at room 
temperature under N2• Sodium methoxide (0.484 g., 0.0098 mole) was 
then added to the reaction mixture which was heated to a boil. The 
mixture turned dark-red and gradually deposited a yellow precipitate. 
Heating was stopped after 75 min.; stirring was continued for 15 min. 
more. When the reaction mixture reached room temperature, 30 ml. of 
absolute methanol was added to dissolve the dark-red precipitate. A 
solution of methyl iodide (0.852 g., 0.006 mole) was then added to the 
reaction mixture and this w,as stirred overnight at room temperature. 
Excess methyl iodide (1 ml.) was again added, and the solution was 
heated gently for 5 min., cooled to room temperature, and then acidified 
with 2N acetic acid.(pH = 6). The mixture was concentrated to a small 
volume (SO ml.) on a rotary evap9rator. 
The resulting tarry substance was triturated with cold distilled 
water (75 ml.). The viscous layer was extracted with ether (2 x 35 ml.) 
and washed with distilled wate;r (3 x 35 ml.) and then with saturated 
NaCl (30 ml.) and finally dried (Mgso4). 
Evaporation of the ether gave a viscous liquid which was dissolved 
in 30 ml. of absolute methanol. Hydrazine (6 g., 95% was added to the 
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reaction mixture under N2• A yellowish precipitate formed after 3 hr. 
of continuous stirring (magnetic stirrer)~ After 2 hr., the mixture 
was diluted with 75 ml. of distilled water for 30 min. The product was 
filtered off under suction, washed (6 x 30 ml.) several times with 
distilled water, and air-dried to give 1.54 g. (70.6%) of 83, m.p. 
232-236°. It was purified by sublimation (150°, 0.01 mm.) to give an 
analytical sample (m.p. 258-260°). The molecular weight determined by 
mass spectral analysis corresponds to 280. 
Anal. Calcd. for c 17H16N2o2 : C, 72.86; H, 5.71; N, 10.00. 
Found: C, 72.73; H, 5.62; N, 9.86. 
IR and NMR analysis (Plates XXIX and XIb) agree with the proposed 
structure for 83. 
Preparation of 4,5-Dihydro-7-methoxynaphth[2,l-d]isoxazole (87). 
----
~his compound was prepared by four different variations of a method in 
order to determine whether two isomers formed and to study the structures 
via PMR and 13cMR analysis.] Method A. 2-Hydroxymethylene compound 93 
----
(1.38 g., 0.0075 mole) was dissolved in 30 ml. of glacial acetic acid 
and hydroxylamine hydrochloride (0.59 g., 0.0085 mole) in 5 ml. of 
distilled water, was then added to the reaction mixture at room 
temperature with constant stirring (magnetic stirrer). The mixture 
was stirred for 48 hr. A red precipitate formed, was filtered out 
under suction, washed several times (6 x 25 ml.) with distilled water, 
and air-dried to give 1. 2 g (88%) of 87, m. p. 59-61 °. Recrystalliza-
~ 
tion of this solid from c 2H50H gave a crystalline material, m.p. 59-61°. 
The proposed molecular weight (201) was confirmed by mass spectral 
analysis. 
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Anal. Calcd. for c12Hi1No 2 : C, 71.64; H, 5.47; N, 6.97. 
Found: C, 72. 01; H, 5. 4 7; N, 6. 92. 
PMR and 13cMR spectra (Plates IXa and Xa) support the suggested 
isomer of the compound !!!. . 
Method B. 2-Hydroxymethylene compound 93 (1. 72 g., 0. 0084 mole) 
----
was dissolved in 25 ml. of acetic acid. A solution of hydroxylamine 
hydrochloride (0.86 g., 0.0124 mole) and sodium acetate (0.86 g., 
0.0105 mole) in 5 ml. of distilled water was added to the mixture1 and 
it was then boiled for 1 hr. and cooled to room temperature. It was 
stirred using a magnetic stirrer. Water (5 ml.) was added to promote 
the formation of precipitate, which was filtered off by suction and 
washed several times (6 x 25 ml.) with distilled water and finally 
air-dried to weigh 1.6 g. (95.2%, of 87a, m.p. 59-61°). A mixed 
melting point determination with 87 confirmed the identity of 87 and 
87a . 
.......... 
This was further proved by NMR spectral analysis. 
Method C. Compound 93 (1.02 g., 0.005 mole) was dissolved in 
-
30 ml. of methanol. A solution of hydroxylamine hydrochloride (1.05 g., 
0.015 mole) and sodium acetate (1.5 g. ~ 0.018 mole) in 5 ml. of dis-
tilled water was added tn the reaction mixture, which was heated 
gently for 0.5 hr. over a steam bath. Upon cooling to room temperature, 
the mixture deposited some solid which was filtered out and washed 
several times (6 x 25 ml.) with distilled water. It was then air-dried 
to give 0.2 g. of a solid (m.p. 141-143°) which was not further 
characterized. 
The filtrate was concentrated to a small volume (:::::::::15 ml.), and 
the resulting waxy liquid was diluted with dilute c2H50H (25 ml.). A 
greenish gummy substance resulted (0.7 g., 69.6%), which proved by its 
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NMR spectrum to be identical with 87 and 87a~ This, on recrystalliza-
tion (95% ethanol), gave 0.7 g. (69%) of 87b, m.p. 59~61°. 
_..... 
Method D. 'ro a solution of hydroxylamine hydrochloride (2.1 g., 
0.03 mole) in 4 ml. of distilled water was added compound~ (2.04 g., 
0.01 mole) in 50 ml. of pyridine, and the reaction mixture was boiled 
for 3 hr. with constant stirring (magnetic stirrer). The solution was 
evaporated to dryness, the residue dissolved in ethanol (95%), and .the 
alcoholic solution kept overnight, without stirring, in the refrige!r-
ator. A greenish gummy substance settled down; the solvent was removed 
by rotary evaporation to give a solid, 2.0 g. (95%). PMR spectral 
analysis (Plate IXb) revealed the fact that thiS compound 87b was not 
-
the same as that from method A, B, or C. On the contrary the presence 
of an isomer of isoxazole was suspected and was confirmed by 13cMR 
spectrum analysis (Plate Xb). 
Preparation of 3,4-Dihydro-1;4-benzothiazepin-5(2H)-one (75). To 
a solution of 0.5 g. (0.0072 mole) of hydroxylamine hydrochloride in 30 
ml. of distilled water was added 2 ml. of an aqueous 10% sodium 
hydroxide and 0.2 g. (0.0012 mole) of thiochroman-4-one. Just enough 
95% ethanol (~ 1 ml.) was added to the reaction mi~ture to give a clear 
solution. It was then warmed on a steam bath for 15 min. and cooled in 
an ice-water bath. A white precipitate formed, this was filtered off, 
washed several times (6 x 25 ml.) with distilled water, and air-dried 
to give 0.2 g. (91.7%) of the oxime 74, m.p. 98-100°. The structure of 
-
74 was confirmed by NMR analysis (Plate XIIa) which was consistent with 
"" 
the reported values for 74. Upon standing for one year in an amber-
_.__. 
colored bottle, the crude solid oxime changed from a white crystalline 
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solid to a red, waxy one. The NMR spectrum indicated the formation of 
the lactam. This phemomenon was again noticed two days after a freshly 
prepared sample of the oxime had been dissolved in DCC13 . The spectrum 
of the sample .was found to be identical with that of the lactam 75 
described earlier. This Beckmann-type rearrangement was further con-
firmed by the demonstration of the reaction betweel'.1 the oxime and a 
couple of drops of cone. HCl when these were kept bvernight and again 
by the NMR spectrum of the product (Plate XIIb). 
Anal. Calcd. for c9H9No: S, 17.88. 
Found: S, 17.85. 
Preparation of 2-Hydroxymethylene-2-methoxybenzosuberone (96). To 
a stirred suspension of sodium methoxide (1.08 g., 0.02 mole) in 20 ml. 
of dry benzene was added 1.48 g. (0.02 mole) of ethyl formate. The 
system was kept under N2 flow and cooled to 10°C by using an ice bath. 
To this cooled solution was added 2.0 g. (0.0105 mole) of 2-methoxy-
benzosuberone in 20 ml. of dry benzene. The reaction mixture turned 
yellow and a yellowish-red precipitate formed after 5 min. This was 
allowed to stand overnight at room temperature. 
Hydrolysis of the reaction mixture was effected with 200 ml. of 
ice-cold water, and the resulting organic layer was washed successively 
with distilled water and an aqueous solution of 10% NaOH. The aqueous 
portions were combined, washed with ether (50 ml.), and then acidified 
with dil HCl in ice. A reddish-brown, heavy liquid formed and was 
extracted with ether (3 x 25 ml.), washed (saturated NaCl, 30 ml.), and 
then dried (Mgso4). Evaporation of the ether gave 2.2 g. (95.9%) of 96 
-
as a waxy reddish-brown oil which was used in the following procedures 
without further purification. The structure was characterized by NMR 
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(Plate XI!Ib) analysis. The molecular weight deterni·ined by mass 
spectral analysis was 218. 
;t ~ 
Preparation of l,4,5,6-Tetrahydro-8-methoxybenzo[6,7Jcyclohepta-
[l,2-c]pyrazole (85). The 2-hydroxymethylene compound 96 (1.3 g., 
-""- ....._ 
0.0059 mole) was dissolved in 40 ml. of anhydrous methanol and to this 
solution was added 3 ml. of 97% hydrazine with constant stirring 
(magnetic stirrer). The reaction was carried out under N2. The mixture 
was stirred for 6 hr. at room temperature. It was diluted ~ith 75 ml. 
of distilled water, boiled for 0.5 hr., and cooled to room temperature. 
Upon cooling in ice, the solution deposited yellow crystals which were 
filtered off under suction and air-dried to give 0.8 g. (62.9%) of 85, 
......... 
m.p. 91-96°. Recrystallization from ethanol (95%) gave an analytical 
sample, m.p. 101-103°. NMR spectral data (Plate XIVa) were in agree-
ment with the proposed structure for 85. The molecular weight by mass 
....._ 
spectral analysis was 214 (calcd. for c13H14N2o). Peak matching using 
PFK confirmed the proposed structure for 85. 
-
M.S. Calcd. for Cl3Hl4N20: m/e 214.112591 (W°) 
Found: m/e 214.110607 (Mt) 
Anal. Calcd. for c13H14N20: N, 13.08. 
Found: N, 12.98. 
Preparation of 5,6-Dihydro-8-methoxy-4H-benzo[3,4]cyclohepta-
[l,2-d]isoxazole (84). To a solution of 2-hydroxymethylene compound 96 
"'""""' ""'-
(0.5 g., 0.0023 mole) in 35 ml. of glacial acetic acid was added 
hydroxylamine hydrochloride (0.248 g., 0.0036 mole) in 5 ml. of water; 
this solution was heated gently for 0.5 hr. with stirring (magnetic 
stirrer) and then cooled to room temperature. After being stirred 
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overnight, the mixture was diluted with cold water (75 ml.). The red 
oily substance formed was separated by extraction with ether. Evapora-
tion of ether on a rotary evaporator gave a dark waxy liquid which on 
recrystallization (95% ethanol) gave 0.4 g. (81.6%) of 84, m.p. 52-53°. 
,,...... 
Anal. Calcd. for c13H13No2 : C, 72.55; H, 6.05; N, 6.51. 
Found: C, 72.10; H, 6.15; N, 6.28. 
NMR spectral analysis (Plate XIVb) confirmed the suggested struc-
.ture for ~· This was reconfirmed by peak matching using PFK. 
M.S. Calcd. for c13H13No2 : m/e 215.094623 (M+) 
Found: m/e 215.094309 (~) 
Preparation of 2-Hydroxyrnethylene-6-methoxy-l-lndanone (95). 
Sodium methoxide (1.08 g., 0.02 mole) was suspended in 20 ml. of 
anhydrous benzene under N2. Ethyl formate (1.48 g., 0.02 mole) was 
then added, and the mixture was cooled to about 10° using ah ice bath 
and with magnetic stirring. A solution of 6-methoxy-1-indanone (2.0 g., 
0.0123 mole) in 20 ml. of anhydrous benzene was added dropwise to the 
reaction mixture, the temperature being kept between 10-15°C (ice 
bath). After the addition was complete, the reaction mixture was 
allowed to warm to room temperature and allowed to stand for 2 hr. 
Hydrolysis was effected with 100 ml. of cold water, and the resulting 
organic layer was washed successively with distilled water (30 ml.) and 
with aqueous 10% NaOH (30 ml.). The combined aqueous extracts were 
washed (ether 3 x 25 ml.) and then acidified with dil HCl to pH = 6. 
Yellow crystals formed and were separated by filtration under suction. 
The crystals were washed several times (distilled water, 3 x 30 ml.) and 
air-dried to give 2.2 g. (94%) of 95, m.p. 149-150°. The proposed 
___,, 
structure was confirmed by molecular weight determination (190) via mass 
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spectral analysis and NMR analysis (Plate XVb). 
In a similar preparation, only the reactiort time for synthesis was 
increased to about 12 hr. The yield of 2-hydroxyrnethylene compound 95 
-
remained unchanged (94%) (m.p. 151°) in what was otherwise an identical 
preparation. 
Preparation of 2~Hydroxymethylene-5,6-dirnethoxy-l-indanone (98) • 
......... 
To a stirred suspension of sodium methoxide (1.08 g., 0.02 mole) in 
30 ml. of dry benzene under N2 was added 1.48 g. (0.02 mole) of ethyl 
formate. 5,6-Dimethoxy-l-indanone (2.0 g., 0.01 mole) in 30 ml. of dry 
benzene was then added drop by drop to the suspension, which was then 
gently warmed for 5 min. A reddish-yellow precipitate formed. The 
reaction mixture was allowed to stand 2 hr. at room temperature with 
constant stirring. Hydrolysis of the reaction mixture was effected with 
100 ml. ice-cold water, and the resulting organic layer was washed 
successively with distilled water (30 ml.) and with aqueous 10% NaOH 
solution (30 ml.). The combined aqueo~s extracts were washed with 
ether (2 x 25 ml.) and then acidified with dil HCl (pH= 6). A yellow-
ish-brown puffy substanced formed and was filtered off. It was washed 
several times (6 x 25 ml.) with distilled water and air-dried to give 
2.2 g. (96.1%) of 98, m.p. 151°. The molecular weight was determined 
--... 
by mass spectral analysis to be 220. 
Anal. Calcd. for c12H12o4 : C, 65.45; H, 5.45. 
Found: C, 65.37; H, 5.39. 
NMR spectral analysis (Plate XVIb) confirmed the proposed structure 
for 98. 
"""""'" 
In another preparation the reaction was carried out under the same 
conditions (compare with 95) except for a longer reaction time (about 
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12 hf.). The yield remained unchanged, but the purity of sample was 
less (m.p. 145-147°), 
Preparation of N-:-Methyl-6-methbxy-l:-tetralone imine (86). To a 
,,..., 
dry, nitrogen-purged, four-necked, 500-ml. reaction vessel equipped with 
an addition funnel, dry-ice condenser, mechanical stirrer, and gas inlet 
tube was added a solution of 6-methoxytetralone (10.0 g., 0.057 mole) 
in 125 ml. of anhydrous ether. The reaction vessel was cooled to below 
-18° (ice-methyl alcohol mixture) and an excess of anhydrous methylamine 
(25 ml.) was distilled into the reaction flask. Methylamine was already 
liquified by cooling the gas to -18° (ice-methanol). 
A solution of titanium tetrachloride (5.7 g., 0.03 mole) in 100 ml. 
of dry n-pentane was added dropwise with stirring over a 1-hr. period. 
(TiC14 was weighed under N2.) After the addition was complete, the 
reaction mixture was stirred at room temperature for 1 hr. It was then 
diluted with 100 ml. of dry ether and filtered by sudtion. The 
filtrate was concentrated (SO ml.) and cooled in the regrigerator over-
night. A crystalline solid formed and was filtered off, washed several 
times (6 x 30 ml.) with ice cold anhydrous !!.-pentane, and dried under 
vacuum to give 10.5 g. (95.85%) of 86 (m.p. 53-55°). The molecular 
-""' 
weight found by mass spectral analysis was 189. 
Anal. Calcd. for c12H15NO: C, 76.19; H, 7.93; N, 7.40. 
Found: C, 76.36; H, 8.14; N, 7.24. 
NMR and IR spectral data (Plates XXIIb and !Vb) confirmed the 
proposed structure. 
General Procedure for Investigation of Molecular Complexes. Com-
pounds under investigation were prepared in our laboratories and 
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purified by either recrystallization or by sublimation. In each case 
the proposed structure was confirmed by NMR, IR, and mass spectral data 
along with elemental analysis prior to use in the cornple:icatiort studies. 
The ultraviolet absorption measurements (on a dary 14 spectropho-
tometer) of the molecular complexes and individual ct;>mponents were per-
formed using quartz cells of 1 mm.; and the NMR studies were carried 
out using 5 mm. (O.D.) tubes maintaining the spin rate at 30 r.p.s. 
Relatively concentrated solutions were first prepared (for UV 
·studies) by accurately weighing out the appropriate samples in separate 
glass~stoppered, 50 ml. volumetric flasks and diluting to volume with 
95% ethanol. The final solutions were then prepared by pipeting a 
portion of this solution into a separate volumetric flask and diluting 
to the desired volume. The concentrations used are given in Tables XV 
and XVIII. The NMR solutions were made up by dissolving accurately 
weighed appropriate samples in suitable deuteriated NMR solvents. All 
runs and measurements were repeated for the sake of completeness and 
deviation was less than 2% of the absolute values obtained. 
A. Molecular Complexation Studies Between 1,4-Dihydro[l]benzo-
thiopyrano[4,3-c]pyrazole (65) and 1,3,5-Trinitrobenzene (121). The 
......- ~ 
following procedure is characteristic of that employed for the compounds 
65 and 121. The general procedure described above was followed to 
obtain NMR and UV spectral data (Tables XIV and XV) on the mixture as 
well as of the unbound (free) reactants. Certain key regions in the NMR 
spectra of the mixture and of the corresponding regions in the spectra 
of the. free components have been expanded for the sake of clarity and 
improved resolution-. 
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A sample of the compound 65 (0.0453 g., 2.409 x 10-4 mole) was 
dissolved in 1 ml. of acetone-~6 (99.5%) with a resulting concentration 
of 2.409 x io-1 mole/liter. An equimolar solution of the acceptor 
(0.0~}3 g., 2.409 x 10-4 mole) was prepared in a similar fashion. A 
1:1 mixture of the compounds ~ and~ was also made following the same 
procedure, and the solutions were then examined via NMR analysis (Table 
XIV). Ultraviolet absorption maxima for the individual compounds and 
the resulting mixture in 95% ethanol (9.63 x lo-5 mole/liter each) were 
also determined (Table XV). 
The formation of a molecular complex was deduced from the NMR data, 
which included chemical shift differences (~v) derived by comparison of 
the spectra of the unbound reactants and complexed reactants. A 
reasonable structure for the complex consiste~t with the observed shift 
trends and intensity was then postulated (Figure 10). 
The evaluation of the association constant, K, was carried using 
116 the Hanna and Ashbaugh method. For reasons of availability of 
material and solubility of same, concentration of the acceptor candidate 
was used in excess. 
The association constant, K, was calculated using the equation 
[A]K (1) 
where oD b = observed chemical shift of the selected donor protons in 
0 s 
the complexing medium; oD is the chemical shift of selected donor 
0 
protons in the uncomplexed state; and oDAD is the shift of selected 
donor protons in the pure complex. A simplified version of the above 
equation assumes the form (2) as shown below: 
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· [A]K 
1 + [A]K /J.o (2) 
where 
and 
The reciprocal of equation (2) gives a new form which is represented by 
(3) 
1 1 1 . 1 
-;;-b = K/J. [A] + T 
o s 0 0 
(3) 
1 To obtain the value of K, a plot was made (Figure 11) of ~~ versus 
/J.obs 
1 [A]" From they-intercept and slope obtained from the graph, the 
association constant, K, was computed and found to be 1.74 i/m, which is 
in good agreement with the reported K values of related systems such as 
the !,!-dimethylaniline-1,4-dinitrobenzene complex (K = 0.05 i/m) and 
the pentamethylbenzene-1,3,5-trinitrobenzene complex (K = 1.93 i/m). 
T.he general procedure was used to investigate molecular complexes 
for the following systems as in the previous procedure A. 
B. The molecular complex involving 1,4-dihydro[l]benzothiopyrano-
[4,3-c]pyrazole (65) and 4-fluorophenylacetonitrile (122). 
- --... ,...,._ 
C. The molecular complex involving pyrazole 65 and 3,4-dihydroxy-
benzoic acid (123). In this case, the temperature dependence of the 
spin-spin relaxation times of the mixture was analyzed by measuring 
the width of the resonance signal at half height (!J.V112) and using the 
relationship T = 2 sec. (Table XIX). 
2 /J.Vl/2 
~. The molecular complex between pyrazole 65 and 5-fluorouracil 
(~). 
E. The molecular complex between 4!:!-[llbenzothi0pyrano[3,4-~]­
isoxazole (68) and 5-fluorouracil (42). 
~ 
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F. The molecular complex between 4,5-dihydro-6,7,8-trimethoxy-l!!-
benz [g] indazole (132) and 5-fluorouracil· (42). 
- "'"""- ---
PMR analysis of these systems reveal a pref erred organization of 
both the donor and acceptor in the complexes. The nature of the complex 
and the factors influencing the complexation process have been discussed 
(Discussion, pages 110-132). 
A Study of the Spectra and Acidity of 4,5-Dihydro-lH-benz[g]-
indazol-7-ol (82) and 2,3a,4,5-Tetrahydro-7-hydroxy-3a-methyl-3H-benz-
-"'- . 
[g]indazol-3-one (80). All experimental pH measurements were made on 
a Beckman 101900 research pH meter with a readability of 0.005 pH units. 
The glass electrode used was Beckman 39301 electrode. As external 
reference electrode, a Beckman calomel electrode was employed. The 
titration was carried out using a Gilmont ultraprecision micrometer 
burette. The pH meter was standardized employing "pHydrion buffers" of 
pH 6.86 and 9.4. 
The compound 80 (6.0 x lo-3 g.; 2.78 x 10-5 mole) was carefully 
-
weighed and dissolved in 28.90 ml. of 1.443 x lo-3 N NaOH. This solu-
tion was degassed with N2 for 15 min. prior to titration, and then it 
was titrated against standard 2.780 x lo-2 N HCl. A magnetic stirrer 
was used during the titration. For indazolone .§.£, the pKa value was 
found to be 8.7. 
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Indazole 82 (5.2 x 10-3 g.; 2.78 x lo-5 mole) was carefully 
""""' 
weighed and dissolved in 21. 7 ml. of 1. 443 x 10-3 ~ NaOH and diluted to 
200 ml. with doubly distilled water. This solution also was degassed 
with N2 for 15 tnin. prior to titration, and then it was titrated against 
'I· 
5.56 x 10-2 N HCl. For the compound ~' the pKa value was found to be 
9.1. 
Indazole 82 (1~12 x lo-4 mole/liter) in water was used for the 
--
purpose of UV spectra1 studies. UV spectra at'3 different pH values: 
3.2, 6, and 9.6 were analyzed. The ultraviolet absorption data (Tables 
XII and XIII) for 80 and 82 are interpreted as supportive of the pro-
. - ...... 
posed tautomeric structures. 
Attempted Preparation of 3-Benzyloxyacrylonitrile (124). Cyanb-
......._ 
acetylene (10.0 g., 0.196 mole) in 100 ml. of anhydrous ether was stir-
red into a suspension of 4.10 g. (0.379 mole) of benzyl alcohol and 5.0 
g. atom) of sodium metal in 100 ml. of dry ether under dry ice-methanol 
cooling system (-75°). The reaction mixture was stirred (magnetic 
stirrer) overnight at room temperature under N2 • A 9lack-colored solid 
appeared as soon as cyanoacetylene was added dropwise. After stirring 
overnight under N2 , the solvents were removed by evaporation (rotary 
evaporator). The residue was a black tarry substance. Attempts were 
made to recrystallize it but to no avail. Formation of a polymeric 
substance was inferred as suggested by its insolubility in many readily 
available organic solvents. 
1.{' 
Attempted Preparation of 7-Methoxy-2,3a,4,5-tetrahydrobenz[g]indol-
3-one (125). To a solution of 6-methoxytetralone (5.28 g., 0.03 mole) 
.~ 
and ethyl a-aminoacetate hydrochloride (4.185 g., 0.03 mole) in 100 ml. 
of toluene was added 6.72 g. (0.06 mole) of potassium !_-butoxide and 
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the reaction mixture was stirred (magnetic) at room temperature. A 
reddish, powder formed an an exothermic .reaction ehsued with a sudden 
rise in temperature of the reaction mixture (to~ 40°). It was then 
heated gently to 80° for 0.5 hr. and cooled to room temperature. 
Acidification (cone. HCl) was performed while cooling the flask in an 
ice bath; the solution was then extracted (ether, 3 x 25 ml.). Both 
layers were separately chilled in a refrigerator overnight. No 
precipitate formed. 
A small portion of the nonaqueous layer was treated with n-hexane 
and cooled in ice. A brown solid formed and was filtered out by 
suction, washed several times (water, 6 x 25 ml.), and air-dried to 
give 0.6 g. of a product. NMR analysis of this solid revealed an 
unexpected substance of very high melting point (m.p. > 325°). 
Interestingly, the aqueous layer turned red in acid medium, green-
brown in neutral medium, and yellowish-brown in basic medium. No 
identifiable solid product could be isolated from the reaction mixture. 
Attempted Preparation of 7-Methoxy-l-methyl-4,5-dihydrobenz[g]indol-
3-(2H)-one (126). To a dry, nitrogen-filled, 3-necked flask equipped 
with a condenser and serum cap was added 5.93 g. (0.0314 mole) of the 
imine 86 in 6 ml. of THF. Isopropylmagnesium chloride (40 ml.) in THF 
~ 
was then slowly added to the reaction mixture via a syringe at a rate 
which maintained a gentle ref lex. To the resulting mixture was added 
4.52 g. (0.04 mole) of chloroacetyl chloride at such a rate that boiling 
was maintained. The reaction mixture turned blood-red color. On 
completion of the addition of chloroacetyl chloride, an additional 
20 ml. of the Grignard reagent was added to the mixture all at one time. 
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The reaction mixture was then diluted with 50 ml. of 1.0 M. 
" aqueous solution of EDTA tetrasodium salt and 150 ml. of 1:1 ether-
benzene solution. The organic layer was separated by extracting with 
water (3 x 25 ml., found to be basic). The process of extraction was 
continued until the solution was neutral. The separated organic layer 
was finally extracted with saturated NaCl and dried (Na2so4) overnight. 
The solution was then filtered by suction, the solvent was removed from 
the filtrate on a rotary evaporator, and the concentrate stored in the 
refrigerator. No crystals formed. GLC analysis showed only two 
compounds--solvent (benzene) and the product. 
tAttempted Preparation of l,4-Dihydro-6,7-dimethoxyindeno[l,2-_.:=.J-
pyrazole (127). Hydroxyrnethylene compound 98 (0.5 g., 0.0023 mole) was 
............ ,...___... 
dissolved in 40 ml. of absolute methanol, and to this solution was added 
1 ml. of 97% hydrazine with constant stirring (magnetic stirrer) under 
N2 . The reaction mixture turned from yellow to orange color and was 
stirred (6 hr.) at room temperature. It was then diluted with 75 ml. 
of cold distilled water, boiled for 0.5 hr., and cooled to room 
temperature. Upon cooling in ice, orange crystals formed; these were 
filtered off under suction and air-dried to give 0.1 g of 127 (m.p. 
"""'-" 
211-212°). The molecular weight determined by mass spectral analysis 
was 464 instead of the proposed molecular weight of 216 (Calcd. for 
c12H12N2o2). Due to its severe insolubility in organic solvents an NMR 
spectrum of the compound 127 could not be obtained without excessive 
time averaging (estimate one to two weeks without Fourier transform and 
pulse equipment). 
Attempted Preparation of 6,7-Dimethoxy-4H-indeno[2,l-d]isoxazole 
(128). To a solution of 2-hydroxyrnethylene compound 98 (0.5 g., 
.......... 
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0. 0023 mole) in 35 ml. of glacial acetic acid was added 0. 207 g. (0. 003 
mole) of hydroxylamine hydrochloride in 5 ml. of distilled water. This 
. It 
solution was heated gently for 0.5 hr. with stirring (magnetic stirrer) 
and then cooled to room temperature. After stirring (magnetic) over-
night, the mixture was tirturated with cold distilled water. The dark-
.red crystals formed and were filtered off under suction and air-dried 
to give 0.3 g. of 128 (m.p. 225-228° with shrinking at 218°). The 
.--
molecular weight found by mass spectral analysis was 467, but the 
expected molecular weight (Calcd. for c12H11No3) for ~ was 217. 
Again, NMR spectral analysis was not rewarding owing to the extreme 
insolubility of the product. 
,.Attempted Preparation of Pyrazolone of Thiochroman-e-one (129) • 
-
Thiochroman-4-one (90) (5.3 g., 0.0323 mole) and 1.89 g. (0.035 mole) 
...-..-
of sodium methoxide were dissolved in 75 ml. of anhydrous dimethyl 
carbonate (distilled with NaH). The reaction mixture 1-las boiled under 
N2 for 3 hr. The mixture turned red within 5 min. It was cooled to 
room temperature and then a portion of it (30 ml.) was acidified (dil 
HCl). No precipitate formed. This solution was concentrated to a 
small volume (15 ml.) by evaporation (rotary evaporator) and cooled 
(ice/H2o bath). It was then filtered under suction and .a black tarry 
substance was isolated. Attempts were made to dissolve it in acetone. 
The part insoluble in acetone was then filtered off by suction. and 
washed several times with cold distilled water. It was air-dried to 
give a yellow-colored solid (2.2 g., m.p. 215-217°). The molecular 
weight determined by mass spectral analysis was 534 instead of the 
expected molecular weight 222 for the keto ester intermediate for the 
preparation of pyrazolone 129. 
--
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Because of the extreme insolubility of this solid in common organic 
solvents, an NMR spectrum of the aforementioned material could not be 
obtain.ed in a single solvent. Fortunately the solid was found to be 
partially soluble in pyridine--~5 . A drop of CF3co2H was added to the 
'Ii 
mixture to increase the solubility. Interestingly, a white, powdery 
solid formed and was filtered off by suction. The white solid was 
insoluble in both organic as well as inorganic solvents. The same sub-
stance formed when pyridine and CF3co2H were mixed (an exothermic 
reaction ensued with a great evolution of heat). The white powdery 
substance formed was found to be very similar to tef loh in appearance 
and solubility. 
Since the compound could not be characterized as the expected 
keto ester intermediate, further attempts to cyclize it to the 
pyrazolone 129 were not pursued • 
.............. 
Attempted Preparation of N,N-Dimethyl-6-methoxytetralone iminium 
iodide (130). 
---
Imine 86 (0.5 g., 0.0027 mole) was dissolved in 50 ml. 
of anhydrous ether and to this solution was· added 2 ml. of methyl 
iodide. The solution was then boiled for 24 hr. A precipitate formed 
and was filtered off, washed with ether, and air-dried to yield 0.06 g. 
of a solid (m.p. 198.5-199°). 
An aqueous AgN03 solution gave a yellow precipitate, which indi-
cated the presence of iodide ion. The elemental analysis was unsatis-
factory. No further work was done. 
Anal. Calcd. for c13H18NO: C, 47.13; H, 5.44; N, 4.23. 
Found: C, 44.56; H~ 4.91; N, 4.52. 
Attempted Preparation of 3,4-Dihydro-3-ethoxy-3-(6-methoxy-l-oxo-
(2H)-2-naphthyl)propionic acid (~). To a magnetically stirred solution 
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of 6-methoxytetralone (7. 6 g., 0. 043 mole) in 125 ml. of dry THF was 
added 4.0 g. (0.08 mole) of sodium methoxide, A solution of 8.0 g. 
(0.06 mole) of ethoxymethylene malononitrile in 25 ml. of THF was then 
added. As the reaction progressed, the mixture darkened. After boiling 
for 15 min. heating was stopped, but stirring was continued overnight. 
To the resulting reaction mixture was added ether (SO ml.) .and the 
solution was filtered by suction. The solid obtained was redissolved 
in water which was acidified (dil HCl) (pH= 6). A precipitate formed 
and was filtered off and air-dried to give 2.0 g. (m.p. 200-214°) of a 
solid. This solid was then magnetically stirred into 100 ml. of 95% 
ethanol, and to this mixture was added excess NaOH (15.0 g.) dissolved 
in 100 ml. of distilled water. The resulting reaction mixture was 
boiled for 100 hr. Evolution of NH3 gas was indicative of the progress 
of reaction. It was finally diluted with. distilled water and washed 
with ether (3 x 25 ml.) . The water layer was then acidified (dil HCl) 
and chilled in the refrigerator. A solid formed and was filtered off, 
washed several times with distilled water and air-dried to weigh 0.8 g. 
(m.p. > 340°). Attempted purification and characterization of the com-
pound did not prove fruitful owing to its extreme insolubility in 
essentially all solvents used. 
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VIIa. 6-Methoxy-1-tetralone (89) 
Solvent ... DCC13 O.F. 
S.W. .1000 Hz S.T. 
Lock . . . . HOMO 
.100.l MHz F.B. 
. .250 Sec S.O. 
.2 R.F. 
83701 Hz S.A. 
Vllb. 2(Hydroxymethylene)6-methoxy-l-tetralone (93) 
,,..._.. 
Solvent. .DCCl3 O.F. .100.1 MHz F.B. . 2 R.F. 
s .w. .1000 Hz S.T. . .500 Sec s. o. 83701 Hz S .A. . 
Lock . . . . HOMO 
. 
.65 dB 
. .1. 6 
66 dB 
. 3.2 
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PLATE VIII 
VIIIa. [(l,2,3,4-Tetrahydr0-6-meth0xy-l-0x0-2-naphthyl)-
methylene]urea (76) 
Solvent .. DMS0-~6 
S.W. .1000 Hz 
Lock •. HOMO 
9 
.......... 
O.F ... 100.1 MHz 
S.T .•.. 500 Sec 
7 
F .B. . • • • 2 R.F ... 68 dB 
S.O ..• 83701 Hz S .A. • • • • 2 
VIIIb. [(l,2,3,4-Tetrahydr0-6-methoxy-l-0xo-2-naphthyl)-
methylene[-2-thiourea (77) 
Solvent .. DMS0-~6 
S.W. .1000 Hz 
Lock .... HOMO 
O.F ... 100.1 MHz 
S.T •... 500 Sec 
,,......_,, 
F. B. • • • • • • 2 
S.O ..• 83701 Hz 
R.F •.• 68 dB 
S .A. • • • 2 
11.--J-
sooo 
:lJ:: 
'. 
ID 
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PLATE IX 
IXa. 4 ,5-Dihydrli>-7-meth©xynaphth [2 ,1-gJ is0xaz0le (87) 
, ....... 
Selvent ••• DCCl3 
S.W •••• 1000 Hz 
Leck .• HOMO 
O.F ... 100.l MHz 
S.T •••• 250 Sec 
F.B. .2 
S.O ••• 83701 Hz 
R.F .•• 66 dB 
S.A •••. 10.0 
·;::;:=r=::::::;::i:=:::;J=c;:==:r::::;:==::c;::::=~==:::;r:::::::z;===;:=:;::::=::;:c:=;::=::i::::=:::;:::r:~=t:=:;::; 
~f·: 
'. I 
! 
9 7 3 
.~~I::::::r=====±===:I:::==:C:::=:::::=~ ... ;::::i:::::::::::c=::::r:=:::i:::::::=:::::::i::::::=:;:::=:::t=:=t:=:I=:::±~ 
.. , -,.--,.--.--r---..,---r---,----r.--.-----'T'""-,-----r--,---,,--- ---r-~--.--...----..--
IXb. 4, 5'-Dihydro-7-methoxynaphth [1, 2-_sJ isoxaz0le (88) 
,...._, 
Sel vent. • • DCCl3 0. F. • .100 .1 MHz 
S.W. .1000 Hz S.T •• ~ .250 Sec 
Lock •• HOMO 
F.B . .,, .• · ·••111:• · • • • 2 
S.O. • • 83701 Hz 
R.F. 
S.A .• 
.63dB 
. . . 1 
~f~ I 
'0 
1 
f 
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PLATE X 
.• ; I I 
: 
I·• r j r 
I '· J. ·. '; I I I . ii ':•.I I 
. .. . '-:I •I,! I I :·· •' ,• •, I I 
I I I I I ! I JlJljjjJ~iJll/'"~~·~ 
I. 
Xa. 13 CMR Spectra ef 4,5-Dihydr0-7-methoxynaphth[2,l-£.]-
is0xaz0le c,,~ 
SGlvent. .DCCl3 O.F .•• 100.1 MHz F.B ••••••• 4 R.F. • 72 dB 
S.W. .5000 Hz NG. Scans ••• 770 S.O ••• 39385 Hz· S.A •••• 0.63 
-· 
lr? 
"JCO,@' ' 
•11'.)o 
I 
I 
~~i,JJll· ~~_.,.,,......,_.~111~L 
Xb. 13 CMR Spectra 0£ 4,5-Dihydr0-7-methoxynaphth[l,2-c]-
isoxaz0le (88) 
·'~ 
Solvent ••• DCCl3 O.F ••• 100.1 MHz F.B. • ••. 4 R.F. • 74 dB 
S.W •.•. 5000 Hz NG. Scans .• 2616 S.O ••• 39385 Hz S.A •••• 0.63 
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PLATE XI 
·.:~~~~~~~~~~~~~ 
l 
.. J, 
Xla. 3, 4-Dihydr0-7-meth0xy-l (2H)ph.enanthnme (101) ,...._... 
Solvent. .DCC13 O.F. .100.1 MHz F.B. . . . 2 R.F. . 69 dB 
s.w. .1000 Hz S. T. . . .250 Sec s.o. . 83701 Hz S .A. . . . 2 
LE> ck . . HOMO 
·::~~~~~~~~~~~~b; 
:J:: 
:t 
,f; 
.. 
,1, 
Xlb. 2,10,ll,lla-Tetrahydr0-7-meth0xy-lla-methyl-lH-
phenanthro[l,2-c]pyraz0l-l-0ne (83) 
- r--' 
·Solvent. .DCCl3 O.F. 
S ~ W. .1000 Hz S. T. 
Lock . . .' . HOMO 
.100.1 MHz 
. . 250 Sec 
F.B. 
s.o. 
.2 R.F. 71 dB 
. 83701 Hz S.A .•... 10 
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PLATE XII 
Ii .: i I I I t 
9 5 
XIIa. Thiochreman-4-one oxime (74) 
S0lvent ... DCCl3 
S.W. . .1000 Hz 
Lock . . HOMO 
r 
+ 
'° ~. 
9 
0.F. .100.1 MHz 
S.T .... 250 Sec 
F.B .• 
s. 0. . 
.2 
83701 Hz 
3 
R. F. • 
S .A. • 
., 
69 dB 
. .• 10 
XIIb. 3 ~ 4-Dihydrn-l, 4-benzothiazepin-5-(2.!!)-one (7 5) 
Solvent ... DCC1 3 O.F. 
S.W. .1000 Hz S.T. 
Lock . . . . HOMO 
.100.1 MHz 
. . 250 Sec 
F.B. 
s.o. 
.2 R.F ..• 68 dB 
. 83701 Hz S.A. . . 6.3 
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PLATE XIII 
"-11-:. 
Xllla. 2-Methoxybenzosuberone (92) 
,, _ ....
Solvent •.. DCCl3 
S.W .... 1000 Hz 
Lock .. HOMO 
f ' . 1 ~1: 
-
.• 
"50 £/a°'°" ' 
A'--' 
9 
O.F. .100.1 MHz 
S.T .... 500 Sec 
-
w 
7 5 
. ' ' . 
F. B. • 
s.o. 
.2 
83701 Hz 
1L 'tt 
3 
-
R.F ... 60 dB 
S.A. 1.25 
·-
,_,~ 
~ 
,, 
11' 
I 
"·-~~-~-~~--~--~--=-----r--,-----,--.......-..---.--,--,.---,---,--.-,..,.,~ 
Xlllb. 2-(Hydroxymethylene)2-methoxybenzosuberone (96) 
,....._, 
Solvent ... DCCl3 O.F. 
S.W. .1000 Hz S.T. 
Lock . . • . HOMO 
.100.1 MHz F.F. 
.. 250 sec S.O. 
.2 R.F. . 48 dB 
. 83701 Hz S.A •••• 3.2 
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PLATE XlV 
XIVa. S,6-Dihydro-8-methoxy-4!!_-benzo[3,4]cyclohepta[l,2-d]isoxazole 
(84) . 
,...-.,_,_ 
Solvent. .DCCl3 
S. W. • • .1000 Hz 
0. F. . . 100 .1 MHz 
S. T. . SOO Sec 
F. B. • . • • • • 2 
S.O ... 83701 Hz 
R.F. 
S .A. 
.SS dB 
• • • 4 
L~~c~k=, ·==·:;:=~·=,H~O~M=Q==c::::;:====~':===:;::=~,~',=;r;~',~'~;,~',,~,,=·~:'r;:=:;:;:i;:=:i;:::::;:~'===::;=:::::;:r:'==1=f==i' ~ ~Ci?? ';'I ;L-- I 
" 
., 
XIVb. l,4,S,6-Tetrahydro-8-methoxybenzo[6,7]cyclohepta[l,2-.£_]-
pyrazole (8S) 
Solvent. 
s.w. 
. DCC13 
• 1000 Hz 
Lock • • • • HOMO 
,,,---' 
O.F. 
S.T. 
.100.1 MHz 
• • SOO Sec 
F.B. 
s.o. 
.2 
83701 Hz 
R.F . 
S .A • 
. 66 dB 
• • • 2 
PLATE XV 
-l:: 
i {j I 0 0 
.. CH3 
,I, 
Jl ~ 
' ' 
,, 
9 7 5 3 
'" 
"• 
- -I I 
XV a. 6-Methoxy-1-indanone (95) 
_, 
Solvent. . .DCCl3 O.F. .100.1 MHz F.B . .2 
s .w. . 1000 Hz S.T. . .500 Sec s.o. . . 83701 Hz 
Lock . . HOMO 
XVb. 2-(Hydroxymethylene)6-methoxy-l-indanone 
Solvent. .DCCl3 O.F. .100.1 MHz F.B. . . . . .2 
s. w. . .1000 Hz S.T. . . 500 Sec s.o. 83701 Hz 
Lock . . HOMO 
I 
R.F. 
S .A . 
(95) 
R.F. . 
S .A . . 
184 
\.-••~ 
i 
60 dB 
1.25 
>-11~ 
68 dB 
. 5.0 
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PLATE XVI 
... 
.... 
.. ~, .. 
•l>o •I: 
•• or&o ·~ 
•• 
..-% 0 
" 
CH3 
' 
·- L-+--t-
9 7 5 3 I 
'• ·~ ~~..---ir""'""-r---,-.,.---r--~--..--r:--.---T=C.--....--,----.-,,_,-"""'T-"_.,.....,..,,...,......,..,...,..,...,...,...,.....,....~.,...,.....,..... 
Solvent ... DCCl3 
S.W. .1000 Hz 
Lock .. HOMO 
l 
·i'-· •• 
1 
XVIa. 5,6-Dimethoxy-1-indanone (134) 
O.F ... 100.1 MHz 
S. T. . . 250 Sec 
F.B. .2 
S.O ..• 83701 Hz 
R.F ••• 55 dB 
S .A. • • 4 
!---""------ __, '----
9 5 3 
~ti±:t:::±:t::::::i::C:=±:::::::±:::::=t:::::::::C:::::::::t:'.::::::::~i::::I:::.::.:::w:±l:±::t:::::::::t=:::::c::::±±::tt:t:.±:::tt:i:::::::=:r:.::t:ttt::::;'.::i!ti:::=:C:::::::±±±:tti 
·~,...,......-r---..---.--..---r---r--r-~,~·,_.,--+""-...,-~-.--...,.....,-..,.-,-,-...,.....-,-,-,.,,..,..,.,,_.,-....,...,...,--r-.,...,.....,..... 
XVIb. 
Solvent ... DCCl3 
S.W .... 1000 Hz 
Lock . . . . HOMO 
2-(Hydroxymethylene)5,6-dimethoxy-1-indanone (98) 
,,..,,.,._.,,,. 
O.F. .100.1 MHz 
S.T .•.• 500 Sec 
F. B. • • • . • 2 
S.O. • 83701 Hz 
R.F. • 63 dB 
S.A ..•• 1.25 
11. ' 
290 
~' 
-,-, 
H 
N-N 00) 
ir. acetone d6 
9 
_I, 
8 7 6 
PLATE XVII 
PPM 
' 
>-H~ 
IU 
acetone 
5 3 2 S.O. --- 83701 Hz 
lffl' I Lt I I I I I I •I I Ii!' t 1 j I It I 1 I! 1, I, ! ! ! 1 
1'F I I ' ' I I I I I ' I ' I I 1 I • • I I 1 t t ! 1 ! i 1 I 1 I I 1 t J 1 I ; I ·1 1 ' I I j ' I 1 I b I I : : I 1 1 I 1 1 1 1 I 1 1 1 : 1 I l'c PPM I t!1. Ir !, •!I 11111 ,1J11 .'1111!1111! II 111 
. ' 1' I 
1,4-Dihydr0[l]benz0thi0pyran0[4,3-c]pyraz0le (65) 
r---' 
Selvent ••• DCC13 
s.~ .... 1000 Hz 
Leck • • . • HOMO 
©.F, •• 100.1 MHz 
S.T •••• 500 Sec 
F. B. • • • • • • 2 
S.O •.. 83701 Hz 
R~F. . . 63 dB 
S.A ••.. 6~3 
I-' 
00 
~ 
XVIIIb. 
XVIIIa. 
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PLATE XVIII 
W"YINUMUI CM' 
Thi0chroman-4-one (90) 
WAYkNllMltl CM' 
'"T++-'-t"+T"T-!-~+;+-1-,.'-'~C'"-+-;+;-t-+"-'+t-'7'--+-~i_,.;----+~-t-'~~·~ 
·I+'-+-'+-·-+-- i 00 
~-++++++++.._,.. ............................ +H~·H+TT+++++t-++HH-'f!--.+i-'~·-· -·~-........ ~ •.-'-' 
i -r·:. 
i. . i Li . i . 
. ,_LiJJj' 11·. 
2-(Hydrexymethylene)thiochroman-4-ene (94) 
' .• f 
188 
PLATE XIX 
XIXa. 4H-[l]Benz0thi0pyran0[3,4-.~Jisoxazole (68) 
~ ..... 
XIXb. 4!!,-[l]Benzothi0pyrane[3,4-d]isoxaz0le 5,5-dioxide (72) 
r""-""' 
XXb. 
xxa. 
PLATE XX 
1,4-Dihydr0[l]benzethi0pyran0[4,3-c]pyraz0le (65) 
,....., 
1,4-Dihydro[l]benzothiepyrano[4,3-,£]pyrazole 5,5-dioxide 
(70) 
,,.. ........ 
189 
XXIb. 
XXIa. 
PLATE XXI 
6-Meth0xy-l-tetral0ne (89) 
,,......,, 
!!-Methyl-6-meth0xy-l-tetralone imine (86) 
,---' 
190 
PLATE XXII 
w ... vntNGltt 11~M1..:11Q...s 
XXIIa. l-[(4-0xethiechreman-3-yl)methylene]-2-thiourea (78) 
..,.._, 
XXIIb. [(l,2,3,4-Tetrahydre-6-methoxy-l-0x0-2-naphthyl)-
methylene]-2-thieurea (77) 
. ,--' 
191 
·. 
PLATE XXIII 
XXIIIa. Methyl 6-methexy-2-methyl-1~0x0-l,2,3,4-tetrahydro­
naphthalene-2-carb0xylate (97) 
~ 
W#IVHEl'IGTll 11'\1 Ml(MON~ 
XXIIIb. 2,3a,4,5-Tetrahydre-3a-methyl-7-meth0xy-3!:!_-benz[gJ-
indazol-3-0ne (79) 
, .......... 
192 
193 
PLATE XXIV 
XXIVa. Thi0chr0man-4-ene Oxime (74) 
r·· .. ··"' 
XXIVb. 3 ,4-Dihydro-l, 4-benz0thiazepin-5-(2H)-ene (75) 
XXVb. 
XXVa. 
PLATE XXV 
WAVHEHGTH IN MICIONS 
5,6-Dimethoxy-1-indanone (134) 
,,..-
2-(Hydroxymethylene)S,6-dimethoxy-1-indanone 
194 
(98) 
r--' 
195 
,PLATE XXVI 
XXVIa. 6-Methoxy-1-indanone (95) 
XXVlb. 2-(Hydroxymethylene)6-methoxy-l-indanone (95) 
,,...._ 
XXVlla. 
XXVIIb. 
PLATE XXVll 
[(l,2,3,4-Tetrahydr0-6-meth0xy-l-0xo-2-naphthyl)-
methylene]urea (76) 
.--·-·"' 
2-(Hydroxymethylene)2-methoxybenz0suberone (96) 
196 
PLATE XXVllI 
2,10,11,lla-Tetrahydro-7-methoxy-lla-methyl-lH-phenanthro-
[1,2-.£.]PYrazol-1-one (83) 
,.._., 
197 
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